[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[S. 524 Engrossed Amendment House (EAH)]
<DOC>
In the House of Representatives, U. S.,
May 13, 2016.
Resolved, That the bill from the Senate (S. 524) entitled ``An Act
to authorize the Attorney General to award grants to address the
national epidemics of prescription opioid abuse and heroin use.'', do
pass with the following
AMENDMENTS:
Strike out all after the enacting clause and insert:
SECTION 1. TABLE OF CONTENTS.
The table of contents for this Act is as follows:
Sec. 1. Table of Contents.
TITLE I--PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE
Sec. 101. Development of best practices for the use of prescription
opioids.
TITLE II--COMPREHENSIVE OPIOID ABUSE REDUCTION ACT
Sec. 201. Short title.
Sec. 202. Comprehensive Opioid Abuse Grant Program.
Sec. 203. Audit and accountability of grantees.
Sec. 204. Veterans treatment courts.
Sec. 205. Emergency Federal law enforcement assistance.
Sec. 206. Inclusion of services for pregnant women under family-based
substance abuse grants.
Sec. 207. GAO study and report on Department of Justice programs and
research relative to substance use and
substance use disorders among adolescents
and young adults.
TITLE III--JASON SIMCAKOSKI PROMISE ACT
Sec. 301. Short title.
Sec. 302. Improvement of opioid safety measures by Department of
Veterans Affairs.
Sec. 303. Strengthening of joint working group on pain management of
the Department of Veterans Affairs and the
Department of Defense.
Sec. 304. Review, investigation, and report on use of opioids in
treatment by Department of Veterans
Affairs.
Sec. 305. Mandatory disclosure of certain veteran information to State
controlled substance monitoring programs.
Sec. 306. Modification to limitation on awards and bonuses.
TITLE IV--KINGPIN DESIGNATION IMPROVEMENT ACT
Sec. 401. Short title.
Sec. 402. Protection of classified information in Federal court
challenges relating to designations under
the Narcotics Kingpin Designation Act.
TITLE V--GOOD SAMARITAN ASSESSMENT ACT
Sec. 501. Short title.
Sec. 502. Finding.
Sec. 503. GAO Study on Good Samaritan laws pertaining to treatment of
opioid overdoses.
Sec. 504. Definitions.
TITLE VI--OPEN ACT
Sec. 601. Short title.
Sec. 602. Evaluation of performance of Department of Justice program.
Sec. 603. Evaluation of performance of Department of Health and Human
Services program.
Sec. 604. Definition.
Sec. 605. No additional funds authorized.
Sec. 606. Matters regarding certain Federal law enforcement assistance.
TITLE VII--INFANT PLAN OF SAFE CARE IMPROVEMENT ACT
Sec. 701. Short title.
Sec. 702. Best practices for development of plans of safe care.
Sec. 703. State plans.
Sec. 704. Data reports.
Sec. 705. Monitoring and oversight.
Sec. 706. Rule of construction.
TITLE VIII--NAS HEALTHY BABIES ACT
Sec. 801. Short title.
Sec. 802. GAO report on neonatal abstinence syndrome (NAS).
Sec. 803. Excluding abuse-deterrent formulations of prescription drugs
from the Medicaid additional rebate
requirement for new formulations of
prescription drugs.
Sec. 804. Limiting disclosure of predictive modeling and other
analytics technologies to identify and
prevent waste, fraud, and abuse.
Sec. 805. Medicaid Improvement Fund.
TITLE IX--CO-PRESCRIBING TO REDUCE OVERDOSES ACT
Sec. 901. Short title.
Sec. 902. Opioid overdose reversal drugs prescribing grant program.
Sec. 903. Providing information to prescribers in certain Federal
health care and medical facilities on best
practices for prescribing opioid overdose
reversal drugs.
Sec. 904. Authorization of appropriations.
Sec. 905. Cut-Go Compliance.
TITLE X--IMPROVING TREATMENT FOR PREGNANT AND POSTPARTUM WOMEN ACT
Sec. 1001. Short title.
Sec. 1002. Reauthorization of residential treatment programs for
pregnant and postpartum women.
Sec. 1003. Pilot program grants for State substance abuse agencies.
Sec. 1004. Cut-Go Compliance.
TITLE XI--VETERAN EMERGENCY MEDICAL TECHNICIAN SUPPORT ACT
Sec. 1101. Short title.
Sec. 1102. Assisting veterans with military emergency medical training
to meet requirements for becoming civilian
emergency medical technicians.
TITLE XII--JOHN THOMAS DECKER ACT
Sec. 1201. Short title.
Sec. 1202. Information materials and resources to prevent addiction
related to youth sports injuries.
TITLE XIII--LALI'S LAW
Sec. 1301. Short title.
Sec. 1302. Opioid overdose reversal medication access and education
grant programs.
Sec. 1303. Cut-Go Compliance.
TITLE XIV--REDUCING UNUSED MEDICATIONS ACT
Sec. 1401. Short title.
Sec. 1402. Partial fills of schedule II controlled substances.
TITLE XV--OPIOID REVIEW MODERNIZATION ACT
Sec. 1501. Short title.
Sec. 1502. FDA opioid action plan.
Sec. 1503. Prescriber education.
Sec. 1504. Guidance on evaluating the abuse deterrence of generic solid
oral opioid drug products.
TITLE XVI--EXAMINING OPIOID TREATMENT INFRASTRUCTURE ACT
Sec. 1601. Short title.
Sec. 1602. Study on treatment infrastructure.
TITLE XVII--OPIOID USE DISORDER TREATMENT EXPANSION AND MODERNIZATION
ACT
Sec. 1701. Short title.
Sec. 1702. Finding.
Sec. 1703. Opioid use disorder treatment modernization.
Sec. 1704. Sense of Congress.
Sec. 1705. Partial fills of schedule II controlled substances.
TITLE XVIII--NATIONAL ALL SCHEDULES PRESCRIPTION ELECTRONIC REPORTING
REAUTHORIZATION ACT
Sec. 1801. Short title.
Sec. 1802. Amendment to purpose.
Sec. 1803. Amendments to controlled substance monitoring program.
TITLE I--PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE
SEC. 101. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF PRESCRIPTION
OPIOIDS.
(a) Definitions.--In this section--
(1) the term ``Secretary'' means the Secretary of Health
and Human Services; and
(2) the term ``task force'' means the Pain Management Best
Practices Inter-Agency Task Force convened under subsection
(b).
(b) Inter-Agency Task Force.--Not later than December 14, 2018, the
Secretary, in cooperation with the Secretary of Veterans Affairs, the
Secretary of Defense, and the Administrator of the Drug Enforcement
Administration, shall convene a Pain Management Best Practices Inter-
Agency Task Force to review, modify, and update, as appropriate, best
practices for pain management (including chronic and acute pain) and
prescribing pain medication.
(c) Membership.--The task force shall be comprised of--
(1) representatives of--
(A) the Department of Health and Human Services;
(B) the Department of Veterans Affairs;
(C) the Food and Drug Administration;
(D) the Department of Defense;
(E) the Drug Enforcement Administration;
(F) the Centers for Disease Control and Prevention;
(G) the Health Resources and Services
Administration;
(H) the Indian Health Service;
(I) the National Academy of Medicine;
(J) the National Institutes of Health;
(K) the Office of National Drug Control Policy;
(L) the Substance Abuse and Mental Health Services
Administration; and
(M) the Office of Women's Health;
(2) State medical boards;
(3) subject to subsection (e), physicians, dentists, and
nonphysician prescribers;
(4) hospitals;
(5) subject to subsection (e), pharmacists and pharmacies;
(6) first responders;
(7) experts in the fields of pain research and addiction
research;
(8) experts in the fields of adolescent and young adult
addiction research;
(9) representatives of--
(A) pain management professional organizations;
(B) the mental health treatment community;
(C) the addiction treatment and recovery community;
(D) pain advocacy groups;
(E) veteran service organizations; and
(F) groups with expertise on overdose reversal;
(10) a person in recovery from addiction to medication for
chronic pain;
(11) a person in recovery from addiction to medication for
chronic pain, whose addiction began in adolescence or young
adulthood;
(12) a person with chronic pain;
(13) an expert on active duty military, armed forces
personnel, and veteran health and prescription opioid
addiction;
(14) an expert in the field of minority health; and
(15) other stakeholders, as the Secretary determines
appropriate.
(d) Condition on Participation on Task Force.--An individual
representing a profession or entity described in paragraph (3) or (5)
of subsection (c) may not serve as a member of the task force unless
such individual--
(1) is currently licensed in a State in which such
individual is practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, a State in which the entity is engaged in business);
and
(2) is currently practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, the entity is in operation).
(e) Duties.--The task force shall--
(1) not later than 180 days after the date on which the
task force is convened under subsection (b), review, modify,
and update, as appropriate, best practices for pain management
(including chronic and acute pain) and prescribing pain
medication, taking into consideration--
(A) existing pain management research;
(B) research on trends in areas and communities in
which the prescription opioid abuse rate and fatality
rate exceed the national average prescription opioid
abuse rate and fatality rate;
(C) recommendations from relevant conferences and
existing relevant evidence-based guidelines;
(D) ongoing efforts at the State and local levels
and by medical professional organizations to develop
improved pain management strategies, including
consideration of differences within and between classes
of opioids, the availability of opioids with abuse
deterrent technology, and pharmacological,
nonpharmacological, medical device alternatives to
opioids to reduce opioid monotherapy in appropriate
cases and the coordination of information collected
from State prescription drug monitoring programs for
the purpose of preventing the diversion of pain
medication;
(E) ongoing efforts at the Federal, State, and
local levels to examine the potential benefits of
electronic prescribing of opioids, including any public
comments collected in the course of those efforts;
(F) the management of high-risk populations, other
than populations who suffer pain, who--
(i) may use or be prescribed
benzodiazepines, alcohol, and diverted opioids;
or
(ii) receive opioids in the course of
medical care;
(G) the distinct needs of adolescents and young
adults with respect to pain management, pain
medication, substance use disorder, and medication-
assisted treatment;
(H) the 2016 Guideline for Prescribing Opioids for
Chronic Pain issued by the Centers for Disease Control
and Prevention;
(I) the practice of co-prescribing naloxone for
both pain patients receiving chronic opioid therapy and
patients being treated for opioid use disorders;
(J) research that has been, or is being, conducted
or supported by the Federal Government on prevention
of, treatment for, and recovery from substance use by
and substance use disorders among adolescents and young
adults relative to any unique circumstances (including
social and biological circumstances) of adolescents and
young adults that may make adolescent-specific and
young adult-specific treatment protocols necessary,
including any effects that substance use and substance
use disorders may have on brain development and the
implications for treatment and recovery;
(K) Federal non-research programs and activities
that address prevention of, treatment for, and recovery
from substance use by and substance use disorders among
adolescents and young adults, including an assessment
of the effectiveness of such programs and activities
in--
(i) preventing substance use by and
substance use disorders among adolescents and
young adults;
(ii) treating such adolescents and young
adults in a way that accounts for any unique
circumstances faced by adolescents and young
adults; and
(iii) supporting long-term recovery among
adolescents and young adults; and
(L) gaps that have been identified by Federal
officials and experts in Federal efforts relating to
prevention of, treatment for, and recovery from
substance use by and substance use disorders among
adolescents and young adults, including gaps in
research, data collection, and measures to evaluate the
effectiveness of Federal efforts, and the reasons for
such gaps;
(2) solicit and take into consideration public comment on
the practices developed under paragraph (1), amending such best
practices if appropriate;
(3) develop a strategy for disseminating information about
the best practices developed under paragraphs (1) and (2) to
prescribers, pharmacists, State medical boards, educational
institutions that educate prescribers and pharmacists, and
other parties, as the Secretary determines appropriate;
(4) review, modify, and update best practices for pain
management and prescribing pain medication, specifically as it
pertains to physician education and consumer education; and
(5) examine and identify--
(A) the extent of the need for the development of
new pharmacological, nonpharmacological, and medical
device alternatives to opioids;
(B) the current status of research efforts to
develop such alternatives; and
(C) the pharmacological, nonpharmacological, and
medical device alternatives to opioids that are
currently available that could be better utilized.
(f) Consideration of Study Results.--In reviewing, modifying, and
updating, best practices for pain management and prescribing pain
medication, the task force shall take into consideration existing
private sector, State, and local government efforts related to pain
management and prescribing pain medication.
(g) Limitation.--The task force shall not have rulemaking
authority.
(h) Report.--Not later than 270 days after the date on which the
task force is convened under subsection (b), the task force shall
submit to Congress a report that includes--
(1) the strategy for disseminating best practices for pain
management (including chronic and acute pain) and prescribing
pain medication, as developed under subsection (e);
(2) the results of a feasibility study on linking the best
practices described in paragraph (1) to receiving and renewing
registrations under section 303(f) of the Controlled Substances
Act (21 U.S.C. 823(f));
(3) recommendations for effectively applying the best
practices described in paragraph (1) to improve prescribing
practices at medical facilities, including medical facilities
of the Veterans Health Administration and Indian Health
Service;
(4) the modified and updated best practices described in
subsection (e)(4); and
(5) the results of the examination and identification
conducted pursuant to subsection (e)(4), and recommendations
regarding--
(A) the development of new pharmacological,
nonpharmacological, and medical device alternatives to
opioids; and
(B) the improved utilization of pharmacological,
nonpharmacological, and medical device alternatives to
opioids that are currently available.
TITLE II--COMPREHENSIVE OPIOID ABUSE REDUCTION ACT
SEC. 201. SHORT TITLE.
This title may be cited as the ``Comprehensive Opioid Abuse
Reduction Act of 2016''.
SEC. 202. COMPREHENSIVE OPIOID ABUSE GRANT PROGRAM.
(a) In General.--Title I of the Omnibus Crime Control and Safe
Streets Act of 1968 (42 U.S.C. 3711 et seq.) is amended by adding at
the end the following:
``PART LL--COMPREHENSIVE OPIOID ABUSE GRANT PROGRAM
``SEC. 3021. DESCRIPTION.
``(a) Grants Authorized.--From amounts made available to carry out
this part, the Attorney General may make grants to States, units of
local government, and Indian tribes, for use by the State, unit of
local government, or Indian tribe to provide services primarily
relating to opioid abuse, including for any one or more of the
following:
``(1) Developing, implementing, or expanding a treatment
alternative to incarceration program, which may include--
``(A) pre-booking or post-booking components, which
may include the activities described in part DD or HH
of this title;
``(B) training for criminal justice agency
personnel on substance use disorders and co-occurring
mental illness and substance use disorders;
``(C) a mental health court, including the
activities described in part V of this title;
``(D) a drug court, including the activities
described in part EE of this title;
``(E) a veterans treatment court program, including
the activities described in subsection (i) of section
2991 of this title;
``(F) a focus on parents whose incarceration could
result in their children entering the child welfare
system; and
``(G) a community-based substance use diversion
program sponsored by a law enforcement agency.
``(2) In the case of a State, facilitating or enhancing
planning and collaboration between State criminal justice
agencies and State substance abuse systems in order to more
efficiently and effectively carry out programs described in
paragraph (1) that address problems related to opioid abuse.
``(3) Providing training and resources for first responders
on carrying and administering an opioid overdose reversal drug
or device approved by the Food and Drug Administration, and
purchasing such a drug or device for first responders who have
received such training to carry and administer.
``(4) Investigative purposes to locate or investigate
illicit activities related to the unlawful distribution of
opioids.
``(5) Developing, implementing, or expanding a medication-
assisted treatment program used or operated by a criminal
justice agency, which may include training criminal justice
agency personnel on medication-assisted treatment, and carrying
out the activities described in part S of this title.
``(6) In the case of a State, developing, implementing, or
expanding a prescription drug monitoring program to collect and
analyze data related to the prescribing of schedules II, III,
and IV controlled substances through a centralized database
administered by an authorized State agency, which includes
tracking the dispensation of such substances, and providing for
interoperability and data sharing with other States.
``(7) Developing, implementing, or expanding a program to
prevent and address opioid abuse by juveniles.
``(8) Developing, implementing, or expanding an integrated
and comprehensive opioid abuse response program, including
prevention and recovery programs.
``(9) Developing, implementing, or expanding a program
(which may include demonstration projects) to utilize
technology that provides a secure container for prescription
drugs that would prevent individuals, particularly adolescents,
from gaining access to opioid medications that are lawfully
prescribed for other individuals.
``(10) Developing, implementing, or expanding a program to
prevent and address opioid abuse by veterans.
``(11) Developing, implementing, or expanding a
prescription drug take-back program.
``(b) Contracts and Subawards.--A State, unit of local government,
or Indian tribe may, in using a grant under this subpart for purposes
authorized by subsection (a), use all or a portion of that grant to
contract with or make one or more subawards to one or more--
``(1) local or regional organizations that are private and
nonprofit, including faith-based organizations;
``(2) units of local government; or
``(3) tribal organizations.
``(c) Program Assessment Component; Waiver.--
``(1) Program assessment component.--Each program funded
under this subpart shall contain a program assessment
component, developed pursuant to guidelines established by the
Attorney General, in coordination with the National Institute
of Justice.
``(2) Waiver.--The Attorney General may waive the
requirement of paragraph (1) with respect to a program if, in
the opinion of the Attorney General, the program is not of
sufficient size to justify a full program assessment.
``(d) Administrative Costs.--Not more than 10 percent of a grant
made under this subpart may be used for costs incurred to administer
such grant.
``(e) Period.--The period of a grant made under this part may not
be longer than 4 years, except that renewals and extensions beyond that
period may be granted at the discretion of the Attorney General.
``SEC. 3022. APPLICATIONS.
``To request a grant under this part, the chief executive officer
of a State, unit of local government, or Indian tribe shall submit an
application to the Attorney General at such time and in such form as
the Attorney General may require. Such application shall include the
following:
``(1) A certification that Federal funds made available
under this subpart will not be used to supplant State, local,
or tribal funds, but will be used to increase the amounts of
such funds that would, in the absence of Federal funds, be made
available for the activities described in section 3021(a).
``(2) An assurance that, for each fiscal year covered by an
application, the applicant shall maintain and report such data,
records, and information (programmatic and financial) as the
Attorney General may reasonably require.
``(3) A certification, made in a form acceptable to the
Attorney General and executed by the chief executive officer of
the applicant (or by another officer of the applicant, if
qualified under regulations promulgated by the Attorney
General), that--
``(A) the programs to be funded by the grant meet
all the requirements of this part;
``(B) all the information contained in the
application is correct;
``(C) there has been appropriate coordination with
affected agencies; and
``(D) the applicant will comply with all provisions
of this part and all other applicable Federal laws.
``(4) An assurance that the applicant will work with the
Drug Enforcement Administration to develop an integrated and
comprehensive strategy to address opioid abuse.
``SEC. 3023. REVIEW OF APPLICATIONS.
``The Attorney General shall not finally disapprove any application
(or any amendment to that application) submitted under this part
without first affording the applicant reasonable notice of any
deficiencies in the application and opportunity for correction and
reconsideration.
``SEC. 3024. EQUITABLE DISTRIBUTION OF FUNDS.
``In awarding grants under this part, the Attorney General shall
ensure equitable distribution of funds based on the following:
``(1) The geographic distribution of grants under this
part, taking into consideration the needs of underserved
populations, including rural and tribal communities.
``(2) The needs of communities to address the problems
related to opioid abuse, taking into consideration the
prevalence of opioid abuse and overdose-related death in a
community.
``SEC. 3025. DEFINITIONS.
``In this part:
``(1) The term `first responder' includes a firefighter,
law enforcement officer, paramedic, emergency medical
technician, or other individual (including an employee of a
legally organized and recognized volunteer organization,
whether compensated or not), who, in the course of professional
duties, responds to fire, medical, hazardous material, or other
similar emergencies.
``(2) The term `medication-assisted treatment' means the
use of medications approved by the Food and Drug Administration
for the treatment of opioid abuse.
``(3) The term `opioid' means any drug, including heroin,
having an addiction-forming or addiction-sustaining liability
similar to morphine or being capable of conversion into a drug
having such addiction-forming or addiction-sustaining
liability.
``(4) The term `schedule II, III, or IV controlled
substance' means a controlled substance that is listed on
schedule II, schedule III, or schedule IV of section 202(c) of
the Controlled Substances Act (21 U.S.C. 812(c)).
``(5) The terms `drug' and `device' have the meanings given
those terms in section 201 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 321).
``(6) The term `criminal justice agency' means a State,
local, or tribal--
``(A) court;
``(B) prison;
``(C) jail;
``(D) law enforcement agency; or
``(E) other agency that performs the administration
of criminal justice, including prosecution, pretrial
services, and community supervision.
``(7) The term `tribal organization' has the meaning given
that term in section 4 of the Indian Self-Determination and
Education Assistance Act (25 U.S.C. 450b).''.
(b) Authorization of Appropriations.--Section 1001(a) of the
Omnibus Crime Control and Safe Streets Act of 1968 (42 U.S.C. 3793(a))
is amended by inserting after paragraph (26) the following:
``(27) There are authorized to be appropriated to carry out
part LL $103,000,000 for each of fiscal years 2017 through
2021.''.
SEC. 203. AUDIT AND ACCOUNTABILITY OF GRANTEES.
(a) Definitions.--In this section--
(1) the term ``covered grant program'' means a grant
program operated by the Department of Justice;
(2) the term ``covered grantee'' means a recipient of a
grant from a covered grant program;
(3) the term ``nonprofit'', when used with respect to an
organization, means an organization that is described in
section 501(c)(3) of the Internal Revenue Code of 1986, and is
exempt from taxation under section 501(a) of such Code; and
(4) the term ``unresolved audit finding'' means an audit
report finding in a final audit report of the Inspector General
of the Department of Justice that a covered grantee has used
grant funds awarded to that grantee under a covered grant
program for an unauthorized expenditure or otherwise
unallowable cost that is not closed or resolved during a 12-
month period prior to the date on which the final audit report
is issued.
(b) Audit Requirement.--Beginning in fiscal year 2016, and annually
thereafter, the Inspector General of the Department of Justice shall
conduct audits of covered grantees to prevent waste, fraud, and abuse
of funds awarded under covered grant programs. The Inspector General
shall determine the appropriate number of covered grantees to be
audited each year.
(c) Mandatory Exclusion.--A grantee that is found to have an
unresolved audit finding under an audit conducted under subsection (b)
may not receive grant funds under a covered grant program in the fiscal
year following the fiscal year to which the finding relates.
(d) Reimbursement.--If a covered grantee is awarded funds under the
covered grant program from which it received a grant award during the
1-fiscal-year period during which the covered grantee is ineligible for
an allocation of grant funds under subsection (c), the Attorney General
shall--
(1) deposit into the General Fund of the Treasury an amount
that is equal to the amount of the grant funds that were
improperly awarded to the covered grantee; and
(2) seek to recoup the costs of the repayment to the Fund
from the covered grantee that was improperly awarded the grant
funds.
(e) Priority of Grant Awards.--The Attorney General, in awarding
grants under a covered grant program shall give priority to eligible
entities that during the 2-year period preceding the application for a
grant have not been found to have an unresolved audit finding.
(f) Nonprofit Requirements.--
(1) Prohibition.--A nonprofit organization that holds money
in offshore accounts for the purpose of avoiding the tax
described in section 511(a) of the Internal Revenue Code of
1986, shall not be eligible to receive, directly or indirectly,
any funds from a covered grant program.
(2) Disclosure.--Each nonprofit organization that is a
covered grantee shall disclose in its application for such a
grant, as a condition of receipt of such a grant, the
compensation of its officers, directors, and trustees. Such
disclosure shall include a description of the criteria relied
on to determine such compensation.
SEC. 204. VETERANS TREATMENT COURTS.
Section 2991 of the Omnibus Crime Control and Safe Streets Act of
1968 (42 U.S.C. 3797aa) is amended--
(1) by redesignating subsection (i) as subsection (j); and
(2) by inserting after subsection (h) the following:
``(i) Assisting Veterans.--
``(1) Definitions.--In this subsection:
``(A) Peer to peer services or programs.--The term
`peer to peer services or programs' means services or
programs that connect qualified veterans with other
veterans for the purpose of providing support and
mentorship to assist qualified veterans in obtaining
treatment, recovery, stabilization, or rehabilitation.
``(B) Qualified veteran.--The term `qualified
veteran' means a preliminarily qualified offender who--
``(i) served on active duty in any branch
of the Armed Forces, including the National
Guard or Reserves; and
``(ii) was discharged or released from such
service under conditions other than
dishonorable.
``(C) Veterans treatment court program.--The term
`veterans treatment court program' means a court
program involving collaboration among criminal justice,
veterans, and mental health and substance abuse
agencies that provides qualified veterans with--
``(i) intensive judicial supervision and
case management, which may include random and
frequent drug testing where appropriate;
``(ii) a full continuum of treatment
services, including mental health services,
substance abuse services, medical services, and
services to address trauma;
``(iii) alternatives to incarceration; or
``(iv) other appropriate services,
including housing, transportation, mentoring,
employment, job training, education, or
assistance in applying for and obtaining
available benefits.
``(2) Veterans assistance program.--
``(A) In general.--The Attorney General, in
consultation with the Secretary of Veterans Affairs,
may award grants under this subsection to applicants to
establish or expand--
``(i) veterans treatment court programs;
``(ii) peer to peer services or programs
for qualified veterans;
``(iii) practices that identify and provide
treatment, rehabilitation, legal, transitional,
and other appropriate services to qualified
veterans who have been incarcerated; or
``(iv) training programs to teach criminal
justice, law enforcement, corrections, mental
health, and substance abuse personnel how to
identify and appropriately respond to incidents
involving qualified veterans.
``(B) Priority.--In awarding grants under this
subsection, the Attorney General shall give priority to
applications that--
``(i) demonstrate collaboration between and
joint investments by criminal justice, mental
health, substance abuse, and veterans service
agencies;
``(ii) promote effective strategies to
identify and reduce the risk of harm to
qualified veterans and public safety; and
``(iii) propose interventions with
empirical support to improve outcomes for
qualified veterans.''.
SEC. 205. EMERGENCY FEDERAL LAW ENFORCEMENT ASSISTANCE.
Section 609Y(a) of the Justice Assistance Act of 1984 (42 U.S.C.
10513(a)) is amended by striking ``September 30, 1984'' and inserting
``September 30, 2021''.
SEC. 206. INCLUSION OF SERVICES FOR PREGNANT WOMEN UNDER FAMILY-BASED
SUBSTANCE ABUSE GRANTS.
Part DD of title I of the Omnibus Crime Control and Safe Streets
Act (42 U.S.C. 3797s et seq.) is amended--
(1) in section 2921(2), by inserting before the period at
the end ``or pregnant women''; and
(2) in section 2927--
(A) in paragraph (1)(A), by inserting ``pregnant
or'' before ``a parent''; and
(B) in paragraph (3), by inserting ``or pregnant
women'' after ``incarcerated parents''.
SEC. 207. GAO STUDY AND REPORT ON DEPARTMENT OF JUSTICE PROGRAMS AND
RESEARCH RELATIVE TO SUBSTANCE USE AND SUBSTANCE USE
DISORDERS AMONG ADOLESCENTS AND YOUNG ADULTS.
(a) Study.--The Comptroller General of the United States shall
conduct a study on how the Department of Justice, through grant
programs, is addressing prevention of, treatment for, and recovery from
substance use by and substance use disorders among adolescents and
young adults. Such study shall include an analysis of each of the
following:
(1) The research that has been, and is being, conducted or
supported pursuant to grant programs operated by the Department
of Justice on prevention of, treatment for, and recovery from
substance use by and substance use disorders among adolescents
and young adults, including an assessment of--
(A) such research relative to any unique
circumstances (including social and biological
circumstances) of adolescents and young adults that may
make adolescent-specific and young adult-specific
treatment protocols necessary, including any effects
that substance use and substance use disorders may have
on brain development and the implications for treatment
and recovery; and
(B) areas of such research in which greater
investment or focus is necessary relative to other
areas of such research.
(2) Department of Justice non-research programs and
activities that address prevention of, treatment for, and
recovery from substance use by and substance use disorders
among adolescents and young adults, including an assessment of
the effectiveness of such programs and activities in preventing
substance use by and substance use disorders among adolescents
and young adults, treating such adolescents and young adults in
a way that accounts for any unique circumstances faced by
adolescents and young adults, and supports long term recovery
among adolescents and young adults.
(3) Gaps that have been identified by officials of the
Department of Justice or experts in the efforts supported by
grant programs operated by the Department of Justice relating
to prevention of, treatment for, and recovery from substance
use by and substance use disorders among adolescents and young
adults, including gaps in research, data collection, and
measures to evaluate the effectiveness of such efforts, and the
reasons for such gaps.
(b) Report.--Not later than 2 years after the date of enactment of
this Act, the Comptroller General shall submit to the appropriate
committees of the Congress a report containing the results of the study
conducted under subsection (a), including--
(1) a summary of the findings of the study; and
(2) recommendations based on the results of the study,
including recommendations for such areas of research and
legislative and administrative action as the Comptroller
General determines appropriate.
TITLE III--JASON SIMCAKOSKI PROMISE ACT
SEC. 301. SHORT TITLE.
This title may be cited as the ``Promoting Responsible Opioid
Management and Incorporating Scientific Expertise Act'' or the ``Jason
Simcakoski PROMISE Act''.
SEC. 302. IMPROVEMENT OF OPIOID SAFETY MEASURES BY DEPARTMENT OF
VETERANS AFFAIRS.
(a) Expansion of Opioid Safety Initiative.--
(1) Inclusion of all medical facilities.--Not later than
180 days after the date of the enactment of this Act, the
Secretary of Veterans Affairs shall expand the Opioid Safety
Initiative of the Department of Veterans Affairs to include all
medical facilities of the Department.
(2) Guidance.--The Secretary shall establish guidance that
each health care provider of the Department of Veterans
Affairs, before initiating opioid therapy to treat a patient as
part of the comprehensive assessment conducted by the health
care provider, use the Opioid Therapy Risk Report tool of the
Department of Veterans Affairs (or any subsequent tool), which
shall include information from the prescription drug monitoring
program of each participating State as applicable, that
includes the most recent information to date relating to the
patient that accessed such program to assess the risk for
adverse outcomes of opioid therapy for the patient, including
the concurrent use of controlled substances such as
benzodiazepines, as part of the comprehensive assessment
conducted by the health care provider.
(3) Enhanced standards.--The Secretary shall establish
enhanced standards with respect to the use of routine and
random urine drug tests for all patients before and during
opioid therapy to help prevent substance abuse, dependence, and
diversion, including--
(A) that such tests occur not less frequently than
once each year; and
(B) that health care providers appropriately order,
interpret and respond to the results from such tests to
tailor pain therapy, safeguards, and risk management
strategies to each patient.
(b) Pain Management Education and Training.--
(1) In general.--In carrying out the Opioid Safety
Initiative of the Department, the Secretary shall require all
employees of the Department responsible for prescribing opioids
to receive education and training described in paragraph (2).
(2) Education and training.--Education and training
described in this paragraph is education and training on pain
management and safe opioid prescribing practices for purposes
of safely and effectively managing patients with chronic pain,
including education and training on the following:
(A) The implementation of and full compliance with
the VA/DOD Clinical Practice Guideline for Management
of Opioid Therapy for Chronic Pain, including any
update to such guideline.
(B) The use of evidence-based pain management
therapies, including cognitive-behavioral therapy, non-
opioid alternatives, and non-drug methods and
procedures to managing pain and related health
conditions including medical devices approved or
cleared by the Food and Drug Administration for the
treatment of patients with chronic pain and
complementary alternative medicines.
(C) Screening and identification of patients with
substance use disorder, including drug-seeking
behavior, before prescribing opioids, assessment of
risk potential for patients developing an addiction,
and referral of patients to appropriate addiction
treatment professionals if addiction is identified or
strongly suspected.
(D) Communication with patients on the potential
harm associated with the use of opioids and other
controlled substances, including the need to safely
store and dispose of supplies relating to the use of
opioids and other controlled substances.
(E) Such other education and training as the
Secretary considers appropriate to ensure that veterans
receive safe and high-quality pain management care from
the Department.
(3) Use of existing program.--In providing education and
training described in paragraph (2), the Secretary shall use
the Interdisciplinary Chronic Pain Management Training Team
Program of the Department (or success program).
(c) Pain Management Teams.--
(1) In general.--In carrying out the Opioid Safety
Initiative of the Department, the director of each medical
facility of the Department shall identify and designate a pain
management team of health care professionals, which may include
board certified pain medicine specialists, responsible for
coordinating and overseeing pain management therapy at such
facility for patients experiencing acute and chronic pain that
is non-cancer related.
(2) Establishment of protocols.--
(A) In general.--In consultation with the Directors
of each Veterans Integrated Service Network, the
Secretary shall establish standard protocols for the
designation of pain management teams at each medical
facility within the Department.
(B) Consultation on prescription of opioids.--Each
protocol established under subparagraph (A) shall
ensure that any health care provider without expertise
in prescribing analgesics or who has not completed the
education and training under subsection (b), including
a mental health care provider, does not prescribe
opioids to a patient unless that health care provider--
(i) consults with a health care provider
with pain management expertise or who is on the
pain management team of the medical facility;
and
(ii) refers the patient to the pain
management team for any subsequent
prescriptions and related therapy.
(3) Report.--
(A) In general.--Not later than 1 year after the
date of enactment of this Act, the director of each
medical facility of the Department shall submit to the
Under Secretary for Health and the director of the
Veterans Integrated Service Network in which the
medical facility is located a report identifying the
health care professionals that have been designated as
members of the pain management team at the medical
facility pursuant to paragraph (1).
(B) Elements.--Each report submitted under
subparagraph (A) with respect to a medical facility of
the Department shall include--
(i) a certification as to whether all
members of the pain management team at the
medical facility have completed the education
and training required under subsection (b);
(ii) a plan for the management and referral
of patients to such pain management team if
health care providers without expertise in
prescribing analgesics prescribe opioid
medications to treat acute and chronic pain
that is non-cancer related; and
(iii) a certification as to whether the
medical facility--
(I) fully complies with the
stepped-care model of pain management
and other pain management policies
contained in Directive 2009-053 of the
Veterans Health Administration, or
successor directive; or
(II) does not fully comply with
such stepped-care model of pain
management and other pain management
policies but is carrying out a
corrective plan of action to ensure
such full compliance.
(d) Tracking and Monitoring of Opioid Use.--
(1) Prescription drug monitoring programs of states.--In
carrying out the Opioid Safety Initiative and the Opioid
Therapy Risk Report tool of the Department, the Secretary
shall--
(A) ensure access by health care providers of the
Department to information on controlled substances,
including opioids and benzodiazepines, prescribed to
veterans who receive care outside the Department
through the prescription drug monitoring program of
each State with such a program, including by seeking to
enter into memoranda of understanding with States to
allow shared access of such information between States
and the Department;
(B) include such information in the Opioid Therapy
Risk Report; and
(C) require health care providers of the Department
to submit to the prescription drug monitoring program
of each State information on prescriptions of
controlled substances received by veterans in that
State under the laws administered by the Secretary.
(2) Report on tracking of data on opioid use.--Not later
than 18 months after the date of the enactment of this Act, the
Secretary shall submit to the Committee on Veterans' Affairs of
the Senate and the Committee on Veterans' Affairs of the House
of Representatives a report on the feasibility and advisability
of improving the Opioid Therapy Risk Report tool of the
Department to allow for more advanced real-time tracking of and
access to data on--
(A) the key clinical indicators with respect to the
totality of opioid use by veterans;
(B) concurrent prescribing by health care providers
of the Department of opioids in different health care
settings, including data on concurrent prescribing of
opioids to treat mental health disorders other than
opioid use disorder; and
(C) mail-order prescriptions of opioid prescribed
to veterans under the laws administered by the
Secretary.
(e) Availability of Opioid Receptor Antagonists.--
(1) Increased availability and use.--
(A) In general.--The Secretary shall maximize the
availability of opioid receptor antagonists approved by
the Food and Drug Administration, including naloxone,
to veterans.
(B) Availability, training, and distributing.--In
carrying out subparagraph (A), not later than 90 days
after the date of the enactment of this Act, the
Secretary shall--
(i) equip each pharmacy of the Department
with opioid receptor antagonists approved by
the Food and Drug Administration to be
dispensed to outpatients as needed; and
(ii) expand the Overdose Education and
Naloxone Distribution program of the Department
to ensure that all veterans in receipt of
health care under laws administered by the
Secretary who are at risk of opioid overdose
may access such opioid receptor antagonists and
training on the proper administration of such
opioid receptor antagonists.
(C) Veterans who are at risk.--For purposes of
subparagraph (B), veterans who are at risk of opioid
overdose include--
(i) veterans receiving long-term opioid
therapy;
(ii) veterans receiving opioid therapy who
have a history of substance use disorder or
prior instances of overdose; and
(iii) veterans who are at risk as
determined by a health care provider who is
treating the veteran.
(2) Report.--Not later than 120 days after the date of the
enactment of this Act, the Secretary shall submit to the
Committee on Veterans' Affairs of the Senate and the Committee
on Veterans' Affairs of the House of Representatives a report
on carrying out paragraph (1), including an assessment of any
remaining steps to be carried out by the Secretary to carry out
such paragraph.
(f) Inclusion of Certain Information and Capabilities in Opioid
Therapy Risk Report Tool of the Department.--
(1) Information.--The Secretary shall include in the Opioid
Therapy Risk Report tool of the Department--
(A) information on the most recent time the tool
was accessed by a health care provider of the
Department with respect to each veteran; and
(B) information on the results of the most recent
urine drug test for each veteran.
(2) Capabilities.--The Secretary shall include in the
Opioid Therapy Risk Report tool the ability of the health care
providers of the Department to determine whether a health care
provider of the Department prescribed opioids to a veteran
without checking the information in the tool with respect to
the veteran.
(g) Notifications of Risk in Computerized Health Record.--The
Secretary shall modify the computerized patient record system of the
Department to ensure that any health care provider that accesses the
record of a veteran, regardless of the reason the veteran seeks care
from the health care provider, will be immediately notified whether the
veteran--
(1) is receiving opioid therapy and has a history of
substance use disorder or prior instances of overdose;
(2) has a history of opioid abuse; or
(3) is at risk of becoming an opioid abuser as determined
by a health care provider who is treating the veteran.
(h) Definitions.--In this section:
(1) The term ``controlled substance'' has the meaning given
that term in section 102 of the Controlled Substances Act (21
U.S.C. 802).
(2) The term ``State'' means each of the several States,
territories, and possessions of the United States, the District
of Columbia, and the Commonwealth of Puerto Rico.
SEC. 303. STRENGTHENING OF JOINT WORKING GROUP ON PAIN MANAGEMENT OF
THE DEPARTMENT OF VETERANS AFFAIRS AND THE DEPARTMENT OF
DEFENSE.
(a) In General.--Not later than 90 days after the date of enactment
of this Act, the Secretary of Veterans Affairs and the Secretary of
Defense shall ensure that the Pain Management Working Group of the
Health Executive Committee of the Department of Veterans Affairs-
Department of Defense Joint Executive Committee (Pain Management
Working Group) established under section 320 of title 38, United States
Code, includes a focus on the following:
(1) The opioid prescribing practices of health care
providers of each Department.
(2) The ability of each Department to manage acute and
chronic pain among individuals receiving health care from the
Department, including training health care providers with
respect to pain management.
(3) The use by each Department of complementary and
integrative health and complementary alternative medicines in
treating such individuals.
(4) The concurrent use by health care providers of each
Department of opioids and prescription drugs to treat mental
health disorders, including benzodiazepines.
(5) The practice by health care providers of each
Department of prescribing opioids to treat mental health
disorders.
(6) The coordination in coverage of and consistent access
to medications prescribed for patients transitioning from
receiving health care from the Department of Defense to
receiving health care from the Department of Veterans Affairs.
(7) The ability of each Department to identify and treat
substance use disorders among individuals receiving health care
from that Department.
(b) Coordination and Consultation.--The Secretary of Veterans
Affairs and the Secretary of Defense shall ensure that the working
group described in subsection (a)--
(1) coordinates the activities of the working group with
other relevant working groups established under section 320 of
title 38, United States Code;
(2) consults with other relevant Federal agencies with
respect to the activities of the working group; and
(3) consults with the Department of Veterans Affairs and
the Department of Defense with respect to, reviews, and
comments on the VA/DOD Clinical Practice Guideline for
Management of Opioid Therapy for Chronic Pain, or any successor
guideline, before any update to the guideline is released.
(c) Clinical Practice Guidelines.--
(1) In general.--Not later than 180 days after the date of
the enactment of this Act, the Secretary of Veterans Affairs
and the Secretary of Defense shall issue an update to the VA/
DOD Clinical Practice Guideline for Management of Opioid
Therapy for Chronic Pain.
(2) Matters included.--In conducting the update under
subsection (a), the Pain Management Working Group, in
coordination with the Clinical Practice Guideline VA/DOD
Management of Opioid Therapy for Chronic Pain Working Group,
shall examine whether the Clinical Practical Guideline should
include the following:
(A) Enhanced guidance with respect to--
(i) the coadministration of an opioid and
other drugs, including benzodiazepines, that
may result in life-limiting drug interactions;
(ii) the treatment of patients with current
acute psychiatric instability or substance use
disorder or patients at risk of suicide; and
(iii) the use of opioid therapy to treat
mental health disorders other than opioid use
disorder.
(B) Enhanced guidance with respect to the treatment
of patients with behaviors or comorbidities, such as
post-traumatic stress disorder or other psychiatric
disorders, or a history of substance abuse or
addiction, that requires a consultation or comanagement
of opioid therapy with one or more specialists in pain
management, mental health, or addictions.
(C) Enhanced guidance with respect to health care
providers--
(i) conducting an effective assessment for
patients beginning or continuing opioid
therapy, including understanding and setting
realistic goals with respect to achieving and
maintaining an expected level of pain relief,
improved function, or a clinically appropriate
combination of both; and
(ii) effectively assessing whether opioid
therapy is achieving or maintaining the
established treatment goals of the patient or
whether the patient and health care provider
should discuss adjusting, augmenting, or
discontinuing the opioid therapy.
(D) Guidelines to govern the methodologies used by
health care providers of the Department of Veterans
Affairs and the Department of Defense to taper opioid
therapy when adjusting or discontinuing the use of
opioid therapy.
(E) Guidelines with respect to appropriate case
management for patients receiving opioid therapy who
transition between inpatient and outpatient health care
settings, which may include the use of care transition
plans.
(F) Guidelines with respect to appropriate case
management for patients receiving opioid therapy who
transition from receiving care during active duty to
post-military health care networks.
(G) Guidelines with respect to providing options,
before initiating opioid therapy, for pain management
therapies without the use of opioids and options to
augment opioid therapy with other clinical and
complementary and integrative health services to
minimize opioid dependence.
(H) Guidelines with respect to the provision of
evidence-based non-opioid treatments within the
Department of Veterans Affairs and the Department of
Defense, including medical devices and other therapies
approved or cleared by the Food and Drug Administration
for the treatment of chronic pain as an alternative to
or to augment opioid therapy.
SEC. 304. REVIEW, INVESTIGATION, AND REPORT ON USE OF OPIOIDS IN
TREATMENT BY DEPARTMENT OF VETERANS AFFAIRS.
(a) Comptroller General Report.--
(1) In general.--Not later than 2 years after the date of
the enactment of this Act, the Comptroller General of the
United States shall submit to the Committee on Veterans'
Affairs of the Senate and the Committee on Veterans' Affairs of
the House of Representatives a report on the Opioid Safety
Initiative of the Department of Veterans Affairs and the opioid
prescribing practices of health care providers of the
Department.
(2) Elements.--The report submitted under paragraph (1)
shall include the following:
(A) Recommendations on such improvements to the
Opioid Safety Initiative of the Department as the
Comptroller General considers appropriate.
(B) Information with respect to--
(i) deaths resulting from sentinel events
involving veterans prescribed opioids by a
health care provider of the Department;
(ii) overall prescription rates and
prescriptions indications of opioids to treat
non-cancer, non-palliative, and non-hospice
care patients;
(iii) the prescription rates and
prescriptions indications of benzodiazepines
and opioids concomitantly by health care
providers of the Department;
(iv) the practice by health care providers
of the Department of prescribing opioids to
treat patients without any pain, including to
treat patients with mental health disorders
other than opioid use disorder; and
(v) the effectiveness of opioid therapy for
patients receiving such therapy, including the
effectiveness of long-term opioid therapy.
(C) An evaluation of processes of the Department in
place to oversee opioid use among veterans, including
procedures to identify and remedy potential over-
prescribing of opioids by health care providers of the
Department.
(D) An assessment of the implementation by the
Secretary of the VA/DOD Clinical Practice Guideline for
Management of Opioid Therapy for Chronic Pain.
(b) Quarterly Progress Report on Implementation of Comptroller
General Recommendations.--Not later than 2 years after the date of the
enactment of this Act, and not later than 30 days after the end of each
quarter thereafter, the Secretary of Veterans Affairs shall submit to
the Committee on Veterans' Affairs of the Senate and the Committee on
Veterans' Affairs of the House of Representatives a progress report
detailing the actions by the Secretary during the period covered by the
report to address any outstanding findings and recommendations by the
Comptroller General of the United States under subsection (a) with
respect to the Veterans Health Administration.
(c) Annual Review of Prescription Rates.--Not later than 1 year
after the date of the enactment of this Act, and not less frequently
than annually for the following 5 years, the Secretary shall submit to
the Committee on Veterans' Affairs of the Senate and the Committee on
Veterans' Affairs of the House of Representatives a report, with
respect to each medical facility of the Department of Veterans Affairs,
to collect and review information on opioids prescribed by health care
providers at the facility to treat non-cancer, non-palliative, and non-
hospice care patients that contains, for the 1-year period preceding
the submission of the report, the following:
(1) The number of patients and the percentage of the
patient population of the Department who were prescribed
benzodiazepines and opioids concurrently by a health care
provider of the Department.
(2) The number of patients and the percentage of the
patient population of the Department without any pain who were
prescribed opioids by a health care provider of the Department,
including those who were prescribed benzodiazepines and opioids
concurrently.
(3) The number of non-cancer, non-palliative, and non-
hospice care patients and the percentage of such patients who
were treated with opioids by a health care provider of the
Department on an inpatient-basis and who also received
prescription opioids by mail from the Department while being
treated on an inpatient-basis.
(4) The number of non-cancer, non-palliative, and non-
hospice care patients and the percentage of such patients who
were prescribed opioids concurrently by a health care provider
of the Department and a health care provider that is not health
care provider of the Department.
(5) With respect to each medical facility of the
Department, information on opioids prescribed by health care
providers at the facility to treat non-cancer, non-palliative,
and non-hospice care patients, including information on--
(A) the prescription rate at which each health care
provider at the facility prescribed benzodiazepines and
opioids concurrently to such patients and the aggregate
such prescription rate for all health care providers at
the facility;
(B) the prescription rate at which each health care
provider at the facility prescribed benzodiazepines or
opioids to such patients to treat conditions for which
benzodiazepines or opioids are not approved treatment
and the aggregate such prescription rate for all health
care providers at the facility;
(C) the prescription rate at which each health care
provider at the facility prescribed or dispensed mail-
order prescriptions of opioids to such patients while
such patients were being treated with opioids on an
inpatient-basis and the aggregate of such prescription
rate for all health care providers at the facility; and
(D) the prescription rate at which each health care
provider at the facility prescribed opioids to such
patients who were also concurrently prescribed opioids
by a health care provider that is not a health care
provider of the Department and the aggregate of such
prescription rates for all health care providers at the
facility.
(6) With respect to each medical facility of the
Department, the number of times a pharmacist at the facility
overrode a critical drug interaction warning with respect to an
interaction between opioids and another medication before
dispensing such medication to a veteran.
(d) Investigation of Prescription Rates.--If the Secretary
determines that a prescription rate with respect to a health care
provider or medical facility of the Department conflicts with or is
otherwise inconsistent with the standards of appropriate and safe care,
the Secretary shall--
(1) immediately notify the Committee on Veterans' Affairs
of the Senate and the Committee on Veterans' Affairs of the
House of Representatives of such determination, including
information relating to such determination, prescription rate,
and health care provider or medical facility, as the case may
be; and
(2) through the Office of the Medical Inspector of the
Veterans Health Administration, conduct a full investigation of
the health care provider or medical facility, as the case may
be.
(e) Prescription Rate Defined.--In this section, the term
``prescription rate'' means, with respect to a health care provider or
medical facility of the Department, each of the following:
(1) The number of patients treated with opioids by the
health care provider or at the medical facility, as the case
may be, divided by the total number of pharmacy users of that
health care provider or medical facility.
(2) The average number of morphine equivalents per day
prescribed by the health care provider or at the medical
facility, as the case may be, to patients being treated with
opioids.
(3) Of the patients being treated with opioids by the
health care provider or at the medical facility, as the case
may be, the average number of prescriptions of opioids per
patient.
SEC. 305. MANDATORY DISCLOSURE OF CERTAIN VETERAN INFORMATION TO STATE
CONTROLLED SUBSTANCE MONITORING PROGRAMS.
Section 5701(l) of title 38, United States Code, is amended by
striking ``may'' and inserting ``shall''.
SEC. 306. MODIFICATION TO LIMITATION ON AWARDS AND BONUSES.
Section 705 of the Veterans Access, Choice, and Accountability Act
of 2014 (Public Law 113-146; 38 U.S.C. 703 note) is amended to read as
follows:
``SEC. 705. LIMITATION ON AWARDS AND BONUSES PAID TO EMPLOYEES OF
DEPARTMENT OF VETERANS AFFAIRS.
``The Secretary of Veterans Affairs shall ensure that the aggregate
amount of awards and bonuses paid by the Secretary in a fiscal year
under chapter 45 or 53 of title 5, United States Code, or any other
awards or bonuses authorized under such title or title 38, United
States Code, does not exceed the following amounts:
``(1) With respect to each of fiscal years 2017 through
2021, $230,000,000.
``(2) With respect to each of fiscal years 2022 through
2024, $360,000,000.''.
TITLE IV--KINGPIN DESIGNATION IMPROVEMENT ACT
SEC. 401. SHORT TITLE.
This title may be cited as the ``Kingpin Designation Improvement
Act of 2016''.
SEC. 402. PROTECTION OF CLASSIFIED INFORMATION IN FEDERAL COURT
CHALLENGES RELATING TO DESIGNATIONS UNDER THE NARCOTICS
KINGPIN DESIGNATION ACT.
Section 804 of the Foreign Narcotics Kingpin Designation Act (21
U.S.C. 1903) is amended by adding at the end the following:
``(i) Protection of Classified Information in Federal Court
Challenges Relating to Designations.--In any judicial review of a
determination made under this section, if the determination was based
on classified information (as defined in section 1(a) of the Classified
Information Procedures Act) such information may be submitted to the
reviewing court ex parte and in camera. This subsection does not confer
or imply any right to judicial review.''.
TITLE V--GOOD SAMARITAN ASSESSMENT ACT
SEC. 501. SHORT TITLE.
This title may be cited as the ``Good Samaritan Assessment Act of
2016''.
SEC. 502. FINDING.
The Congress finds that the executive branch, including the Office
of National Drug Control Policy, has a policy focus on preventing and
addressing prescription drug misuse and heroin use, and has worked with
States and municipalities to enact Good Samaritan laws that would
protect caregivers, law enforcement personnel, and first responders who
administer opioid overdose reversal drugs or devices.
SEC. 503. GAO STUDY ON GOOD SAMARITAN LAWS PERTAINING TO TREATMENT OF
OPIOID OVERDOSES.
The Comptroller General of the United States shall submit to the
Committee on the Judiciary of the House of Representatives, the
Committee on Oversight and Government Reform of the House of
Representatives, the Committee on the Judiciary of the Senate, and the
Committee on Homeland Security and Governmental Affairs of the Senate a
report on--
(1) the extent to which the Director of National Drug
Control Policy has reviewed Good Samaritan laws, and any
findings from such a review, including findings related to the
potential effects of such laws, if available;
(2) efforts by the Director to encourage the enactment of
Good Samaritan laws; and
(3) a compilation of Good Samaritan laws in effect in the
States, the territories, and the District of Columbia.
SEC. 504. DEFINITIONS.
In this title--
(1) the term ``Good Samaritan law'' means a law of a State
or unit of local government that exempts from criminal or civil
liability any individual who administers an opioid overdose
reversal drug or device, or who contacts emergency services
providers in response to an overdose; and
(2) the term ``opioid'' means any drug, including heroin,
having an addiction-forming or addiction-sustaining liability
similar to morphine or being capable of conversion into a drug
having such addiction-forming or addiction-sustaining
liability.
TITLE VI--OPEN ACT
SEC. 601. SHORT TITLE.
This title may be cited as the ``Opioid Program Evaluation Act'' or
the ``OPEN Act''.
SEC. 602. EVALUATION OF PERFORMANCE OF DEPARTMENT OF JUSTICE PROGRAM.
(a) Evaluation of Justice Department Comprehensive Opioid Abuse
Grant Program.--Not later than 5 years after the date of enactment of
this Act, the Attorney General shall complete an evaluation of the
effectiveness of the Comprehensive Opioid Abuse Grant Program under
part LL of the Omnibus Crime Control and Safe Streets Act of 1968
administered by the Department of Justice based upon the information
reported under subsection (d) of this section.
(b) Interim Evaluation.--Not later than 3 years after the date of
enactment of this Act, the Attorney General shall complete an interim
evaluation assessing the nature and extent of the incidence of opioid
abuse and illegal opioid distribution in the United States.
(c) Metrics and Outcomes for Evaluation.--Not later than 180 days
after the date of enactment of this Act, the Attorney General shall
identify outcomes that are to be achieved by activities funded by the
Comprehensive Opioid Grant Abuse Program and the metrics by which the
achievement of such outcomes shall be determined.
(d) Metrics Data Collection.--The Attorney General shall require
grantees under the Comprehensive Opioid Abuse Grant Program (and those
receiving subawards under section 3021(b) of part LL of the Omnibus
Crime Control and Safe Streets Act of 1968) to collect and annually
report to the Department of Justice data based upon the metrics
identified under subsection (c).
(e) Publication of Data and Findings.--
(1) Publication of outcomes and metrics.--The Attorney
General shall, not later than 30 days after completion of the
requirement under subsection (c), publish the outcomes and
metrics identified under that subsection.
(2) Publication of evaluation.--In the case of the interim
evaluation under subsection (b), and the final evaluation under
subsection (a), the National Academy of Sciences shall, not
later than 90 days after such an evaluation is completed,
publish the results of such evaluation and issue a report on
such evaluation to the Committee on the Judiciary of the House
of Representatives and the Committee on the Judiciary of the
Senate. Such report shall also be published along with the data
used to make such evaluation.
(f) Arrangement With the National Academy of Sciences.--For
purposes of subsections (a), (b), and (c), the Attorney General shall
enter into an arrangement with the National Academy of Sciences.
SEC. 603. EVALUATION OF PERFORMANCE OF DEPARTMENT OF HEALTH AND HUMAN
SERVICES PROGRAM.
(a) Evaluation of Department of Health and Human Services
Programs.--Not later than 5 years after the date of enactment of this
Act, except as otherwise provided in this section, the Secretary of
Health and Human Services shall complete an evaluation of any program
administered by the Secretary that provides grants for the primary
purpose of providing assistance in addressing problems pertaining to
opioid abuse based upon the information reported under subsection (d)
of this section.
(b) Interim Evaluation.--Not later than 3 years after the date of
enactment of this Act, the Secretary shall complete an interim
evaluation assessing the nature and extent of the incidence of opioid
abuse and illegal opioid distribution in the United States.
(c) Metrics and Outcomes for Evaluation.--Not later than 180 days
after the date of enactment of this Act, the Secretary shall identify
outcomes that are to be achieved by activities funded by the programs
described in subsection (a) and the metrics by which the achievement of
such outcomes shall be determined.
(d) Metrics Data Collection.--The Secretary shall require grantees
under the programs described in subsection (a) to collect and annually
report to the Department of Health and Human Services data based upon
the metrics identified under subsection (c).
(e) Publication of Data and Findings.--
(1) Publication of outcomes and metrics.--The Secretary
shall, not later than 30 days after completion of the
requirement under subsection (c), publish the outcomes and
metrics identified under that subsection.
(2) Publication of evaluation.--In the case of the interim
evaluation under subsection (b), and each final evaluation
under subsection (a), the National Academy of Sciences shall,
not later than 90 days after such an evaluation is completed,
publish the results of such evaluation and issue a report on
such evaluation to the Committee on Energy and Commerce of the
House of Representatives and the Committee on Health,
Education, Labor, and Pensions of the Senate. Such report shall
also be published along with the data used to make such
evaluation.
(f) Arrangement With the National Academy of Sciences.--For
purposes of subsections (a), (b), and (c), the Secretary shall--
(1) enter into an arrangement with the National Academy of
Sciences; or
(2) enter into a contract or cooperative agreement with an
entity that is not an agency of the Federal Government.
(g) Exception.--If a program described under subsection (a) is
subject to an evaluation substantially similar to the evaluation under
subsection (a) pursuant to another provision of law, the Secretary may
opt not to conduct an evaluation under subsection (a) of such program.
SEC. 604. DEFINITION.
In this title, the term ``opioid'' has the meaning given the term
``opiate'' in section 102 of the Controlled Substances Act (21 U.S.C.
802).
SEC. 605. NO ADDITIONAL FUNDS AUTHORIZED.
No additional funds are authorized to be appropriated to carry out
this Act.
SEC. 606. MATTERS REGARDING CERTAIN FEDERAL LAW ENFORCEMENT ASSISTANCE.
Section 609Y of the Justice Assistance Act of 1984 (42 U.S.C.
10513) is amended--
(1) in subsection (a), by striking ``There is'' and
inserting ``Except as provided in subsection (c), there is'';
and
(2) by adding at the end the following:
``(c) For fiscal year 2022, there is authorized to be appropriated
$16,000,000, to provide under this chapter Federal law enforcement
assistance in the form of funds.''.
TITLE VII--INFANT PLAN OF SAFE CARE IMPROVEMENT ACT
SEC. 701. SHORT TITLE.
This title may be cited as the ``Infant Plan of Safe Care
Improvement Act''.
SEC. 702. BEST PRACTICES FOR DEVELOPMENT OF PLANS OF SAFE CARE.
Section 103(b) of the Child Abuse Prevention and Treatment Act (42
U.S.C. 5104(b)) is amended--
(1) by redesignating paragraphs (5) through (8) as
paragraphs (6) through (9), respectively; and
(2) by inserting after paragraph (4), the following:
``(5) maintain and disseminate information about the
requirements of section 106(b)(2)(B)(iii) and best practices
relating to the development of plans of safe care as described
in such section for infants born and identified as being
affected by illegal substance abuse or withdrawal symptoms, or
a Fetal Alcohol Spectrum Disorder;''.
SEC. 703. STATE PLANS.
Section 106(b)(2)(B)(iii) of the Child Abuse Prevention and
Treatment Act (42 U.S.C. 5106a(b)(2)(B)(iii)) is amended by inserting
before the semicolon at the end the following: ``to ensure the safety
and well-being of such infant following release from the care of
healthcare providers, including through--''
``(I) addressing the health and
substance use disorder treatment needs
of the infant and affected family or
caregiver; and
``(II) the development and
implementation by the State of
monitoring systems regarding the
implementation of such plans to
determine whether and in what manner
local entities are providing, in
accordance with State requirements,
referrals to and delivery of
appropriate services for the infant and
affected family or caregiver''.
SEC. 704. DATA REPORTS.
(a) In General.--Section 106(d) of the Child Abuse Prevention and
Treatment Act (42 U.S.C. 5106a(d)) is amended by adding at the end of
the following:
``(17)(A) The number of infants identified under subsection
(b)(2)(B)(ii).
``(B) The number of infants for whom a plan of safe care
was developed under subsection (b)(2)(B)(iii).
``(C) The number of infants for whom a referral was made
for appropriate services, including services for the affected
family or caregiver, under subsection (b)(2)(B)(iii).''.
(b) Redesignation.--Effective on May 29, 2017, section 106(d) of
the Child Abuse Prevention and Treatment Act (42 U.S.C. 5106a(d)) is
amended by redesignating paragraph (17) (as added by subsection (a)) as
paragraph (18).
SEC. 705. MONITORING AND OVERSIGHT.
(a) Amendment.--Title I of the Child Abuse Prevention and Treatment
Act (42 U.S.C. 5101 et seq.) is further amended by adding at the end
the following:
``SEC. 114. MONITORING AND OVERSIGHT.
``The Secretary shall conduct monitoring to ensure that each State
that receives a grant under section 106 is in compliance with the
requirements of section 106(b), which--
``(1) shall--
``(A) be in addition to the review of the State
plan upon its submission under section 106(b)(1)(A);
and
``(B) include monitoring of State policies and
procedures required under clauses (ii) and (iii) of
section 106(b)(2)(B); and
``(2) may include--
``(A) a comparison of activities carried out by the
State to comply with the requirements of section 106(b)
with the State plan most recently approved under
section 432 of the Social Security Act;
``(B) a review of information available on the
Website of the State relating to its compliance with
the requirements of section 106(b);
``(C) site visits, as may be necessary to carry out
such monitoring; and
``(D) a review of information available in the
State's Annual Progress and Services Report most
recently submitted under section 1357.16 of title 45,
Code of Federal Regulations (or successor
regulations).''.
(b) Table of Contents.--The table of contents in section 1(b) of
the Child Abuse Prevention and Treatment Act (42 U.S.C. 5101 note) is
amended by inserting after the item relating to section 113, the
following:
``Sec. 114. Monitoring and oversight.''.
SEC. 706. RULE OF CONSTRUCTION.
Nothing in this Act, or the amendments made by this Act, shall be
construed to authorize the Secretary of Health and Human Services or
any other officer of the Federal Government to add new requirements to
section 106(b) of the Child Abuse Prevention and Treatment Act (42
U.S.C. 5106a(b)), as amended by this Act.
TITLE VIII--NAS HEALTHY BABIES ACT
SEC. 801. SHORT TITLE.
This title may be cited as the ``Nurturing And Supporting Healthy
Babies Act'' or as the ``NAS Healthy Babies Act''.
SEC. 802. GAO REPORT ON NEONATAL ABSTINENCE SYNDROME (NAS).
(a) In General.--Not later than 1 year after the date of the
enactment of this Act, the Comptroller General of the United States
shall submit to the Committee on Energy and Commerce of the House of
Representatives and the Committee on Finance and the Committee on
Health, Education, Labor and Pensions of the Senate a report on
neonatal abstinence syndrome (in this section referred to as ``NAS'')
in the United States.
(b) Information To Be Included in Report.--Such report shall
include information on the following:
(1) The prevalence of NAS in the United States, including
the proportion of children born in the United States with NAS
who are eligible for medical assistance under State Medicaid
programs under title XIX of the Social Security Act at birth
and the costs associated with NAS through such programs.
(2) The services for which coverage is available under
State Medicaid programs for treatment of infants with NAS.
(3) The settings (including inpatient, outpatient,
hospital-based, and other settings) for the treatment of
infants with NAS and the reimbursement methodologies and costs
associated with such treatment in such settings.
(4) The prevalence of utilization of various care settings
under State Medicaid programs for treatment of infants with NAS
and any Federal barriers to treating such infants under such
programs, particularly in non-hospital-based settings.
(5) What is known about best practices for treating infants
with NAS.
(c) Recommendations.--Such report also shall include such
recommendations as the Comptroller General determines appropriate for
improvements that will ensure access to treatment for infants with NAS
under State Medicaid programs.
SEC. 803. EXCLUDING ABUSE-DETERRENT FORMULATIONS OF PRESCRIPTION DRUGS
FROM THE MEDICAID ADDITIONAL REBATE REQUIREMENT FOR NEW
FORMULATIONS OF PRESCRIPTION DRUGS.
(a) In General.--The last sentence of section 1927(c)(2)(C) of the
Social Security Act (42 U.S.C. 1396r-8(c)(2)(C)) is amended by
inserting before the period at the end the following: ``, but does not
include an abuse-deterrent formulation of the drug (as determined by
the Secretary), regardless of whether such abuse-deterrent formulation
is an extended release formulation''.
(b) Effective Date.--The amendment made by subsection (a) shall
apply to drugs that are paid for by a State in calendar quarters
beginning on or after the date of the enactment of this Act.
SEC. 804. LIMITING DISCLOSURE OF PREDICTIVE MODELING AND OTHER
ANALYTICS TECHNOLOGIES TO IDENTIFY AND PREVENT WASTE,
FRAUD, AND ABUSE.
(a) In General.--Title XI of the Social Security Act is amended by
inserting after section 1128J (42 U.S.C. 1320a-7k) the following new
section:
``SEC. 1128K. DISCLOSURE OF PREDICTIVE MODELING AND OTHER ANALYTICS
TECHNOLOGIES TO IDENTIFY AND PREVENT WASTE, FRAUD, AND
ABUSE.
``(a) Reference to Predictive Modeling Technologies Requirements.--
For provisions relating to the use of predictive modeling and other
analytics technologies to identify and prevent waste, fraud, and abuse
with respect to the Medicare program under title XVIII, the Medicaid
program under title XIX, and the Children's Health Insurance Program
under title XXI, see section 4241 of the Small Business Jobs Act of
2010 (42 U.S.C. 1320a-7m).
``(b) Limiting Disclosure of Predictive Modeling Technologies.--In
implementing such provisions under such section 4241 with respect to
covered algorithms (as defined in subsection (c)), the following shall
apply:
``(1) Nonapplication of foia.--The covered algorithms used
or developed for purposes of such section (including by the
Secretary or a State (or an entity operating under a contract
with a State)) shall be exempt from disclosure under section
552(b)(3) of title 5, United States Code.
``(2) Limitation with respect to use and disclosure of
information by state agencies.--
``(A) In general.--A State agency may not use or
disclose covered algorithms used or developed for
purposes of such section except for purposes of
administering the State plan (or a waiver of the plan)
under the Medicaid program under title XIX or the State
child health plan (or a waiver of the plan) under the
Children's Health Insurance Program under title XXI,
including by enabling an entity operating under a
contract with a State to assist the State to identify
or prevent waste, fraud, and abuse with respect to such
programs.
``(B) Information security.--A State agency shall
have in effect data security and control policies that
the Secretary finds adequate to ensure the security of
covered algorithms used or developed for purposes of
such section 4241 and to ensure that access to such
information is restricted to authorized persons for
purposes of authorized uses and disclosures described
in subparagraph (A).
``(C) Procedural requirements.--State agencies to
which information is disclosed pursuant to such section
4241 shall adhere to uniform procedures established by
the Secretary.
``(c) Covered Algorithm Defined.--In this section, the term
`covered algorithm'--
``(1) means a predictive modeling or other analytics
technology, as used for purposes of section 4241(a) of the
Small Business Jobs Act of 2010 (42 U.S.C. 1320a-7m(a)) to
identify and prevent waste, fraud, and abuse with respect to
the Medicare program under title XVIII, the Medicaid program
under title XIX, and the Children's Health Insurance Program
under title XXI; and
``(2) includes the mathematical expressions utilized in the
application of such technology and the means by which such
technology is developed.''.
(b) Conforming Amendments.--
(1) Medicaid state plan requirement.--Section 1902(a) of
the Social Security Act (42 U.S.C. 1396a(a)) is amended--
(A) in paragraph (80), by striking ``and'' at the
end;
(B) in paragraph (81), by striking the period at
the end and inserting ``; and''; and
(C) by inserting after paragraph (81) the following
new paragraph:
``(82) provide that the State agency responsible for
administering the State plan under this title provides
assurances to the Secretary that the State agency is in
compliance with subparagraphs (A), (B), and (C) of section
1128K(b)(2).''.
(2) State child health plan requirement.--Section
2102(a)(7) of the Social Security Act (42 U.S.C. 1397bb(a)(7))
is amended--
(A) in subparagraph (A), by striking ``, and'' at
the end and inserting a semicolon;
(B) in subparagraph (B), by striking the period at
the end and inserting ``; and''; and
(C) by adding at the end the following new
subparagraph:
``(C) to ensure that the State agency involved is
in compliance with subparagraphs (A), (B), and (C) of
section 1128K(b)(2).''.
SEC. 805. MEDICAID IMPROVEMENT FUND.
Section 1941(b)(1) of the Social Security Act (42 U.S.C. 1396w-
1(b)(1)) is amended to read as follows:
``(1) In general.--There shall be available to the Fund,
for expenditures from the Fund for fiscal year 2021 and
thereafter, $5,000,000.''.
TITLE IX--CO-PRESCRIBING TO REDUCE OVERDOSES ACT
SEC. 901. SHORT TITLE.
This title may be cited as the ``Co-Prescribing to Reduce Overdoses
Act of 2016''.
SEC. 902. OPIOID OVERDOSE REVERSAL DRUGS PRESCRIBING GRANT PROGRAM.
(a) Establishment.--
(1) In general.--Not later than 6 months after the date of
the enactment of this Act, the Secretary of Health and Human
Services may establish, in accordance with this section, a 5-
year opioid overdose reversal drugs prescribing grant program
(in this Act referred to as the ``grant program'').
(2) Maximum grant amount.--A grant made under this section
may not be for more than $200,000 per grant year.
(3) Eligible entity.--For purposes of this section, the
term ``eligible entity'' means a federally qualified health
center (as defined in section 1861(aa) of the Social Security
Act (42 U.S.C. 1395x(aa)), an opioid treatment program under
part 8 of title 42, Code of Federal Regulations, any
practitioner dispensing narcotic drugs pursuant to section
303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), or
any other entity that the Secretary deems appropriate.
(4) Prescribing.--For purposes of this section and section
3, the term ``prescribing'' means, with respect to an opioid
overdose reversal drug, such as naloxone, the practice of
prescribing such drug--
(A) in conjunction with an opioid prescription for
patients at an elevated risk of overdose;
(B) in conjunction with an opioid agonist approved
under section 505 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355) for the treatment of
opioid abuse disorder;
(C) to the caregiver or a close relative of
patients at an elevated risk of overdose from opioids;
or
(D) in other circumstances, as identified by the
Secretary, in which a provider identifies a patient is
at an elevated risk for an intentional or unintentional
drug overdose from heroin or prescription opioid
therapies.
(b) Application.--To be eligible to receive a grant under this
section, an eligible entity shall submit to the Secretary of Health and
Human Services, in such form and manner as specified by the Secretary,
an application that describes--
(1) the extent to which the area to which the entity will
furnish services through use of the grant is experiencing
significant morbidity and mortality caused by opioid abuse;
(2) the criteria that will be used to identify eligible
patients to participate in such program; and
(3) how such program will work to try to identify State,
local, or private funding to continue the program after
expiration of the grant.
(c) Use of Funds.--An eligible entity receiving a grant under this
section may use the grant for any of the following activities, but may
use not more than 20 percent of the grant funds for activities
described in paragraphs (4) and (5):
(1) To establish a program for prescribing opioid overdose
reversal drugs, such as naloxone.
(2) To train and provide resources for health care
providers and pharmacists on the prescribing of opioid overdose
reversal drugs, such as naloxone.
(3) To establish mechanisms and processes for tracking
patients participating in the program described in paragraph
(1) and the health outcomes of such patients.
(4) To purchase opioid overdose reversal drugs, such as
naloxone, for distribution under the program described in
paragraph (1).
(5) To offset the co-pays and other cost sharing associated
with opioid overdose reversal drugs, such as naloxone, to
ensure that cost is not a limiting factor for eligible
patients.
(6) To conduct community outreach, in conjunction with
community-based organizations, designed to raise awareness of
prescribing practices, and the availability of opioid overdose
reversal drugs, such as naloxone.
(7) To establish protocols to connect patients who have
experienced a drug overdose with appropriate treatment,
including medication assisted treatment and appropriate
counseling and behavioral therapies.
(d) Evaluations by Recipients.--As a condition of receipt of a
grant under this section, an eligible entity shall, for each year for
which the grant is received, submit to the Secretary of Health and
Human Services information on appropriate outcome measures specified by
the Secretary to assess the outcomes of the program funded by the
grant, including--
(1) the number of prescribers trained;
(2) the number of prescribers who have co-prescribed an
opioid overdose reversal drug, such as naloxone, to at least
one patient;
(3) the total number of prescriptions written for opioid
overdose reversal drugs, such as naloxone;
(4) the percentage of patients at elevated risk who
received a prescription for an opioid overdose reversal drug,
such as naloxone;
(5) the number of patients reporting use of an opioid
overdose reversal drug, such as naloxone; and
(6) any other outcome measures that the Secretary deems
appropriate.
(e) Reports by Secretary.--For each year of the grant program under
this section, the Secretary of Health and Human Services shall submit
to the appropriate committees of the House of Representatives and of
the Senate a report aggregating the information received from the grant
recipients for such year under subsection (d) and evaluating the
outcomes achieved by the programs funded by grants made under this
section.
SEC. 903. PROVIDING INFORMATION TO PRESCRIBERS IN CERTAIN FEDERAL
HEALTH CARE AND MEDICAL FACILITIES ON BEST PRACTICES FOR
PRESCRIBING OPIOID OVERDOSE REVERSAL DRUGS.
(a) In General.--Not later than 180 days after the date of
enactment of this Act, the Secretary of Health and Human Services (in
this section referred to as the ``Secretary'') may, as appropriate,
provide information to prescribers within federally qualified health
centers (as defined in paragraph (4) of section 1861(aa) of the Social
Security Act (42 U.S.C. 1395x(aa))), and the health care facilities of
the Indian Health Service, on best practices for prescribing opioid
overdose reversal drugs, such as naloxone, for patients receiving
chronic opioid therapy, patients being treated for opioid use
disorders, and other patients that a provider identifies as having an
elevated risk of overdose from heroin or prescription opioid therapies.
(b) Not Establishing a Medical Standard of Care.--The information
on best practices provided under this section shall not be construed as
constituting or establishing a medical standard of care for prescribing
opioid overdose reversal drugs, such as naloxone, for patients
described in subsection (a).
(c) Elevated Risk of Overdose Defined.--In this section, the term
``elevated risk of overdose'' has the meaning given such term by the
Secretary, which--
(1) may be based on the criteria provided in the Opioid
Overdose Toolkit published by the Substance Abuse and Mental
Health Services Administration (SAMHSA); and
(2) may include patients on a first course opioid
treatment, patients using extended-release and long-acting
opioid analgesics, and patients with a respiratory disease or
other co-morbidities.
SEC. 904. AUTHORIZATION OF APPROPRIATIONS.
There is authorized to be appropriated to carry out this title
$5,000,000 for the period of fiscal years 2017 through 2021.
SEC. 905. CUT-GO COMPLIANCE.
Subsection (f) of section 319D of the Public Health Service Act (42
U.S.C. 247d-4) is amended by inserting before the period at the end the
following: ``(except such dollar amount shall be reduced by $5,000,000
for fiscal year 2018)''.
TITLE X--IMPROVING TREATMENT FOR PREGNANT AND POSTPARTUM WOMEN ACT
SEC. 1001. SHORT TITLE.
This title may be cited as the ``Improving Treatment for Pregnant
and Postpartum Women Act of 2016''.
SEC. 1002. REAUTHORIZATION OF RESIDENTIAL TREATMENT PROGRAMS FOR
PREGNANT AND POSTPARTUM WOMEN.
Section 508 of the Public Health Service Act (42 U.S.C. 290bb-1) is
amended--
(1) in subsection (p), in the first sentence, by inserting
``(other than subsection (r))'' after ``section''; and
(2) in subsection (r), by striking ``such sums'' and all
that follows through ``2003'' and inserting ``$16,900,000 for
each of fiscal years 2017 through 2021''.
SEC. 1003. PILOT PROGRAM GRANTS FOR STATE SUBSTANCE ABUSE AGENCIES.
(a) In General.--Section 508 of the Public Health Service Act (42
U.S.C. 290bb-1) is amended--
(1) by redesignating subsection (r), as amended by section
2, as subsection (s); and
(2) by inserting after subsection (q) the following new
subsection:
``(r) Pilot Program for State Substance Abuse Agencies.--
``(1) In general.--From amounts made available under
subsection (s), the Director of the Center for Substance Abuse
Treatment shall carry out a pilot program under which
competitive grants are made by the Director to State substance
abuse agencies to--
``(A) enhance flexibility in the use of funds
designed to support family-based services for pregnant
and postpartum women with a primary diagnosis of a
substance use disorder, including opioid use disorders;
``(B) help State substance abuse agencies address
identified gaps in services furnished to such women
along the continuum of care, including services
provided to women in nonresidential based settings; and
``(C) promote a coordinated, effective, and
efficient State system managed by State substance abuse
agencies by encouraging new approaches and models of
service delivery.
``(2) Requirements.--In carrying out the pilot program
under this subsection, the Director shall--
``(A) require State substance abuse agencies to
submit to the Director applications, in such form and
manner and containing such information as specified by
the Director, to be eligible to receive a grant under
the program;
``(B) identify, based on such submitted
applications, State substance abuse agencies that are
eligible for such grants;
``(C) require services proposed to be furnished
through such a grant to support family-based treatment
and other services for pregnant and postpartum women
with a primary diagnosis of a substance use disorder,
including opioid use disorders;
``(D) not require that services furnished through
such a grant be provided solely to women that reside in
facilities;
``(E) not require that grant recipients under the
program make available through use of the grant all
services described in subsection (d); and
``(F) consider not applying requirements described
in paragraphs (1) and (2) of subsection (f) to
applicants, depending on the circumstances of the
applicant.
``(3) Required services.--
``(A) In general.--The Director shall specify a
minimum set of services required to be made available
to eligible women through a grant awarded under the
pilot program under this subsection. Such minimum set--
``(i) shall include requirements described
in subsection (c) and be based on the
recommendations submitted under subparagraph
(B); and
``(ii) may be selected from among the
services described in subsection (d) and
include other services as appropriate.
``(B) Stakeholder input.--The Director shall
convene and solicit recommendations from stakeholders,
including State substance abuse agencies, health care
providers, persons in recovery from substance abuse,
and other appropriate individuals, for the minimum set
of services described in subparagraph (A).
``(4) Duration.--The pilot program under this subsection
shall not exceed 5 years.
``(5) Evaluation and report to congress.--The Director of
the Center for Behavioral Health Statistics and Quality shall
fund an evaluation of the pilot program at the conclusion of
the first grant cycle funded by the pilot program. The Director
of the Center for Behavioral Health Statistics and Quality, in
coordination with the Director of the Center for Substance
Abuse Treatment shall submit to the relevant committees of
jurisdiction of the House of Representatives and the Senate a
report on such evaluation. The report shall include at a
minimum outcomes information from the pilot program, including
any resulting reductions in the use of alcohol and other drugs;
engagement in treatment services; retention in the appropriate
level and duration of services; increased access to the use of
medications approved by the Food and Drug Administration for
the treatment of substance use disorders in combination with
counseling; and other appropriate measures.
``(6) State substance abuse agencies defined.--For purposes
of this subsection, the term `State substance abuse agency'
means, with respect to a State, the agency in such State that
manages the Substance Abuse Prevention and Treatment Block
Grant under part B of title XIX.''.
(b) Funding.--Subsection (s) of section 508 of the Public Health
Service Act (42 U.S.C. 290bb-1), as amended by section 1002 and
redesignated by subsection (a), is further amended by adding at the end
the following new sentence: ``Of the amounts made available for a year
pursuant to the previous sentence to carry out this section, not more
than 25 percent of such amounts shall be made available for such year
to carry out subsection (r), other than paragraph (5) of such
subsection. Notwithstanding the preceding sentence, no funds shall be
made available to carry out subsection (r) for a fiscal year unless the
amount made available to carry out this section for such fiscal year is
more than the amount made available to carry out this section for
fiscal year 2016.''.
SEC. 1004. CUT-GO COMPLIANCE.
Subsection (f) of section 319D of the Public Health Service Act (42
U.S.C. 247d-4) is amended by striking ``through 2018'' and inserting
``through 2016, $133,300,000 for fiscal year 2017, and $138,300,000 for
fiscal year 2018''.
TITLE XI--VETERAN EMERGENCY MEDICAL TECHNICIAN SUPPORT ACT
SEC. 1101. SHORT TITLE.
This title may be cited as the ``Veteran Emergency Medical
Technician Support Act of 2016''.
SEC. 1102. ASSISTING VETERANS WITH MILITARY EMERGENCY MEDICAL TRAINING
TO MEET REQUIREMENTS FOR BECOMING CIVILIAN EMERGENCY
MEDICAL TECHNICIANS.
Part B of title III of the Public Health Service Act (42 U.S.C. 243
et seq.) is amended by inserting after section 314 the following:
``SEC. 315. ASSISTING VETERANS WITH MILITARY EMERGENCY MEDICAL TRAINING
TO MEET REQUIREMENTS FOR BECOMING CIVILIAN EMERGENCY
MEDICAL TECHNICIANS.
``(a) Program.--The Secretary shall establish a program consisting
of awarding demonstration grants to States to streamline State
requirements and procedures in order to assist veterans who completed
military emergency medical technician training while serving in the
Armed Forces of the United States to meet certification, licensure, and
other requirements applicable to becoming an emergency medical
technician in the State.
``(b) Use of Funds.--Amounts received as a demonstration grant
under this section shall be used to prepare and implement a plan to
streamline State requirements and procedures as described in subsection
(a), including by--
``(1) determining the extent to which the requirements for
the education, training, and skill level of emergency medical
technicians in the State are equivalent to requirements for the
education, training, and skill level of military emergency
medical technicians; and
``(2) identifying methods, such as waivers, for military
emergency medical technicians to forgo or meet any such
equivalent State requirements.
``(c) Eligibility.--To be eligible for a grant under this section,
a State shall demonstrate that the State has a shortage of emergency
medical technicians.
``(d) Report.--The Secretary shall submit to the Congress an annual
report on the program under this section.
``(e) Funding.--No additional funds are authorized to be
appropriated for the purpose of carrying out this section. This section
shall be carried out using amounts otherwise available for such
purpose.''.
TITLE XII--JOHN THOMAS DECKER ACT
SEC. 1201. SHORT TITLE.
This title may be cited as the ``John Thomas Decker Act of 2016''.
SEC. 1202. INFORMATION MATERIALS AND RESOURCES TO PREVENT ADDICTION
RELATED TO YOUTH SPORTS INJURIES.
(a) Technical Clarification.--Effective as if included in the
enactment of the Children's Health Act of 2000 (Public Law 106-310),
section 3405(a) of such Act (114 Stat. 1221) is amended by striking
``Part E of title III'' and inserting ``Part E of title III of the
Public Health Service Act''.
(b) Amendment.--Title III of the Public Health Service Act is
amended by inserting after part D of such title (42 U.S.C. 254b et
seq.) the following new part E:
``PART E--OPIOID USE DISORDER
``SEC. 341. INFORMATION MATERIALS AND RESOURCES TO PREVENT ADDICTION
RELATED TO YOUTH SPORTS INJURIES.
``(a) Report.--The Secretary shall--
``(1) not later than 24 months after the date of the
enactment of this section, make publicly available a report
determining the extent to which informational materials and
resources described in subsection (b) are available to
teenagers and adolescents who play youth sports, families of
such teenagers and adolescents, nurses, youth sports groups,
and relevant health care provider groups; and
``(2) for purposes of educating and preventing addiction in
teenagers and adolescents who are injured playing youth sports
and are subsequently prescribed an opioid, not later than 12
months after such report is made publicly available and taking
into consideration the findings of such report, develop and, in
coordination with youth sports groups, disseminate
informational materials and resources described in subsection
(b) for teenagers and adolescents who play youth sports,
families of such teenagers and adolescents, nurses, youth
sports groups, and relevant health care provider groups.
``(b) Materials and Resources Described.--For purposes of this
section, the informational materials and resources described in this
subsection are informational materials and resources with respect to
youth sports injuries for which opioids are potentially prescribed and
subsequently potentially lead to addiction, including materials and
resources focused on the dangers of opioid use and misuse, treatment
options for such injuries that do not involve the use of opioids, and
how to seek treatment for addiction.
``(c) No Additional Funds.--No additional funds are authorized to
be appropriated for the purpose of carrying out this section. This
section shall be carried out using amounts otherwise available for such
purpose.''.
TITLE XIII--LALI'S LAW
SEC. 1301. SHORT TITLE.
This title may be cited as ``Lali's Law''.
SEC. 1302. OPIOID OVERDOSE REVERSAL MEDICATION ACCESS AND EDUCATION
GRANT PROGRAMS.
(a) Technical Clarification.--Effective as if included in the
enactment of the Children's Health Act of 2000 (Public Law 106-310),
section 3405(a) of such Act (114 Stat. 1221) is amended by striking
``Part E of title III'' and inserting ``Part E of title III of the
Public Health Service Act''.
(b) Amendment.--Title III of the Public Health Service Act is
amended by inserting after part D of such title (42 U.S.C. 254b et
seq.) the following new part E:
``PART E--OPIOID USE DISORDER
``SEC. 341. OPIOID OVERDOSE REVERSAL MEDICATION ACCESS AND EDUCATION
GRANT PROGRAMS.
``(a) Grants to States.--The Secretary may make grants to States
for--
``(1) developing standing orders for pharmacies regarding
opioid overdose reversal medication;
``(2) encouraging pharmacies to dispense opioid overdose
reversal medication pursuant to a standing order;
``(3) implementing best practices for persons authorized to
prescribe medication regarding--
``(A) prescribing opioids for the treatment of
chronic pain;
``(B) co-prescribing opioid overdose reversal
medication with opioids; and
``(C) discussing the purpose and administration of
opioid overdose reversal medication with patients;
``(4) developing or adapting training materials and methods
for persons authorized to prescribe or dispense medication to
use in educating the public regarding--
``(A) when and how to administer opioid overdose
reversal medication; and
``(B) steps to be taken after administering opioid
overdose reversal medication; and
``(5) educating the public regarding--
``(A) the public health benefits of opioid overdose
reversal medication; and
``(B) the availability of opioid overdose reversal
medication without a person-specific prescription.
``(b) Certain Requirement.--A grant may be made under this section
only if the State involved has authorized standing orders regarding
opioid overdose reversal medication.
``(c) Preference in Making Grants.--In making grants under this
section, the Secretary shall give preference to States that--
``(1) have not issued standing orders regarding opioid
overdose reversal medication;
``(2) authorize standing orders that permit community-based
organizations, substance abuse programs, or other nonprofit
entities to acquire, dispense, or administer opioid overdose
reversal medication;
``(3) authorize standing orders that permit police, fire,
or emergency medical services agencies to acquire and
administer opioid overdose reversal medication;
``(4) have a higher per capita rate of opioid overdoses
than other applicant States; or
``(5) meet any other criteria deemed appropriate by the
Secretary.
``(d) Grant Terms.--
``(1) Number.--A State may not receive more than one grant
under this section.
``(2) Period.--A grant under this section shall be for a
period of 3 years.
``(3) Amount.--A grant under this section may not exceed
$500,000.
``(4) Limitation.--A State may use not more than 20 percent
of a grant under this section for educating the public pursuant
to subsection (a)(5).
``(e) Applications.--To be eligible to receive a grant under this
section, a State shall submit an application to the Secretary in such
form and manner and containing such information as the Secretary may
require, including detailed proposed expenditures of grant funds.
``(f) Reporting.--Not later than 3 months after the Secretary
disburses the first grant payment to any State under this section and
every 6 months thereafter for 3 years, such State shall submit a report
to the Secretary that includes the following:
``(1) The name and ZIP Code of each pharmacy in the State
that dispenses opioid overdose reversal medication under a
standing order.
``(2) The total number of opioid overdose reversal
medication doses dispensed by each such pharmacy, specifying
how many were dispensed with or without a person-specific
prescription.
``(3) The number of pharmacists in the State who have
participated in training pursuant to subsection (a)(4).
``(g) Definitions.--In this section:
``(1) Opioid overdose reversal medication.--The term
`opioid overdose reversal medication' means any drug, including
naloxone, that--
``(A) blocks opioids from attaching to, but does
not itself activate, opioid receptors; or
``(B) inhibits the effects of opioids on opioid
receptors.
``(2) Standing order.--The term `standing order' means a
document prepared by a person authorized to prescribe
medication that permits another person to acquire, dispense, or
administer medication without a person-specific prescription.
``(h) Authorization of Appropriations.--
``(1) In general.--To carry out this section, there is
authorized to be appropriated $5,000,000 for the period of
fiscal years 2017 through 2019.
``(2) Administrative costs.--Not more than 3 percent of the
amounts made available to carry out this section may be used by
the Secretary for administrative expenses of carrying out this
section.''.
SEC. 1303. CUT-GO COMPLIANCE.
Subsection (f) of section 319D of the Public Health Service Act (42
U.S.C. 247d-4) is amended by inserting before the period at the end the
following: ``(except such dollar amount shall be reduced by $5,000,000
for fiscal year 2017)''.
TITLE XIV--REDUCING UNUSED MEDICATIONS ACT
SEC. 1401. SHORT TITLE.
This title may be cited as the ``Reducing Unused Medications Act of
2016''.
SEC. 1402. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES.
(a) In General.--Section 309 of the Controlled Substances Act (21
U.S.C. 829) is amended by adding at the end the following:
``(f) Partial Fills of Schedule II Controlled Substances.--
``(1) Partial fills.--
``(A) In general.--A prescription for a controlled
substance in schedule II may be partially filled if--
``(i) it is not prohibited by State law;
``(ii) the prescription is written and
filled in accordance with the Controlled
Substances Act (21 U.S.C. 801 et seq.),
regulations prescribed by the Attorney General,
and State law;
``(iii) the partial fill is requested by
the patient or the practitioner that wrote the
prescription; and
``(iv) the total quantity dispensed in all
partial fillings does not exceed the total
quantity prescribed.
``(B) Other circumstances.--A prescription for a
controlled substance in schedule II may be partially
filled in accordance with section 1306.13 of title 21,
Code of Federal Regulations (as in effect on the date
of enactment of the Reducing Unused Medications Act).
``(2) Remaining portions.--
``(A) In general.--Except as provided in
subparagraph (B), remaining portions of a partially
filled prescription for a controlled substance in
schedule II--
``(i) may be filled; and
``(ii) shall be filled not later than 30
days after the date on which the prescription
is written.
``(B) Emergency situations.--In emergency
situations, as described in subsection (a), the
remaining portions of a partially filled prescription
for a controlled substance in schedule II--
``(i) may be filled; and
``(ii) shall be filled not later than 72
hours after the prescription is issued.''.
(b) Rule of Construction.--Nothing in this section shall be
construed to affect the authority of the Attorney General to allow a
prescription for a controlled substance in schedule III, IV, or V of
section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) to
be partially filled.
TITLE XV--OPIOID REVIEW MODERNIZATION ACT
SEC. 1501. SHORT TITLE.
This title may be cited as the ``Opioid Review Modernization Act of
2016''.
SEC. 1502. FDA OPIOID ACTION PLAN.
Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by
inserting after section 569 of such Act (21 U.S.C. 350bbb-8) the
following:
``SEC. 569-1. OPIOID ACTION PLAN.
``(a) New Drug Application.--
``(1) In general.--Subject to paragraph (2), prior to the
approval pursuant to an application under section 505(b) of a
new drug that is an opioid and does not have abuse-deterrent
properties, the Secretary shall refer the application to an
advisory committee of the Food and Drug Administration to seek
recommendations from such advisory committee.
``(2) Public health exemption.--A referral to an advisory
committee under paragraph (1) is not required with respect to a
new drug if the Secretary--
``(A) finds that such a referral is not in the
interest of protecting and promoting public health;
``(B) finds that such a referral is not necessary
based on a review of the relevant scientific
information; and
``(C) submits a notice containing the rationale for
such findings to the Committee on Health, Education,
Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representatives.
``(b) Pediatric Opioid Labeling.--The Secretary shall convene the
Pediatric Advisory Committee of the Food and Drug Administration to
seek recommendations from such Committee regarding a framework for the
inclusion of information in the labeling of drugs that are opioids
relating to the use of such drugs in pediatric populations before the
Secretary approves any labeling or change to labeling for any drug that
is an opioid intended for use in a pediatric population.
``(c) Sunset.--The requirements of subsections (a) and (b) shall
cease to be effective on October 1, 2022.''.
SEC. 1503. PRESCRIBER EDUCATION.
Not later than 1 year after the date of the enactment of this Act,
the Secretary of Health and Human Services, acting through the
Commissioner of Food and Drugs, as part of the Food and Drug
Administration's evaluation of the Extended-Release/Long-Acting Opioid
Analgesics Risk Evaluation and Mitigation Strategy, and in consultation
with relevant stakeholders, shall develop recommendations regarding
education programs for prescribers of opioids pursuant to section 505-1
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1),
including recommendations on--
(1) which prescribers should participate in such programs;
and
(2) how often participation in such programs is necessary.
SEC. 1504. GUIDANCE ON EVALUATING THE ABUSE DETERRENCE OF GENERIC SOLID
ORAL OPIOID DRUG PRODUCTS.
Not later than 2 years after the end of the period for public
comment on the draft guidance entitled ``General Principals for
Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug
Products'' issued by the Center for Drug Evaluation and Research of the
Food and Drug Administration in March 2016, the Commissioner of Food
and Drugs shall publish in the Federal Register a final version of such
guidance.
TITLE XVI--EXAMINING OPIOID TREATMENT INFRASTRUCTURE ACT
SEC. 1601. SHORT TITLE.
This title may be cited as the ``Examining Opioid Treatment
Infrastructure Act of 2016''.
SEC. 1602. STUDY ON TREATMENT INFRASTRUCTURE.
Not later than 24 months after the date of enactment of this Act,
the Comptroller General of the United States shall initiate an
evaluation, and submit to Congress a report, of the inpatient and
outpatient treatment capacity, availability, and needs of the United
States, which shall include, to the extent data are available--
(1) the capacity of acute residential or inpatient
detoxification programs;
(2) the capacity of inpatient clinical stabilization
programs, transitional residential support services, and
residential rehabilitation programs;
(3) the capacity of demographic specific residential or
inpatient treatment programs, such as those designed for
pregnant women or adolescents;
(4) geographical differences of the availability of
residential and outpatient treatment and recovery options for
substance use disorders across the continuum of care;
(5) the availability of residential and outpatient
treatment programs that offer treatment options based on
reliable scientific evidence of efficacy for the treatment of
substance use disorders, including the use of Food and Drug
Administration-approved medicines and evidence-based
nonpharmacological therapies;
(6) the number of patients in residential and specialty
outpatient treatment services for substance use disorders;
(7) an assessment of the need for residential and
outpatient treatment for substance use disorders across the
continuum of care;
(8) the availability of residential and outpatient
treatment programs to American Indians and Alaska Natives
through an Indian health program (as defined by section 4 of
the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
(9) the barriers (including technological barriers) at the
Federal, State, and local levels to real-time reporting of de-
identified information on drug overdoses and ways to overcome
such barriers.
TITLE XVII--OPIOID USE DISORDER TREATMENT EXPANSION AND MODERNIZATION
ACT
SEC. 1701. SHORT TITLE.
This title may be cited as the ``Opioid Use Disorder Treatment
Expansion and Modernization Act''.
SEC. 1702. FINDING.
The Congress finds that opioid use disorder has become a public
health epidemic that must be addressed by increasing awareness and
access to all treatment options for opioid use disorder, overdose
reversal, and relapse prevention.
SEC. 1703. OPIOID USE DISORDER TREATMENT MODERNIZATION.
(a) In General.--Section 303(g)(2) of the Controlled Substances Act
(21 U.S.C. 823(g)(2)) is amended--
(1) in subparagraph (B), by striking clauses (i), (ii), and
(iii) and inserting the following:
``(i) The practitioner is a qualifying practitioner (as
defined in subparagraph (G)).
``(ii) With respect to patients to whom the practitioner
will provide such drugs or combinations of drugs, the
practitioner has the capacity to provide directly, by referral,
or in such other manner as determined by the Secretary--
``(I) all schedule III, IV, and V drugs, as well as
unscheduled medications approved by the Food and Drug
Administration, for the treatment of opioid use
disorder, including such drugs and medications for
maintenance, detoxification, overdose reversal, and
relapse prevention, as available; and
``(II) appropriate counseling and other appropriate
ancillary services.
``(iii)(I) The total number of such patients of the
practitioner at any one time will not exceed the applicable
number. Except as provided in subclause (II), the applicable
number is 30.
``(II) The applicable number is 100 if, not sooner than 1
year after the date on which the practitioner submitted the
initial notification, the practitioner submits a second
notification to the Secretary of the need and intent of the
practitioner to treat up to 100 patients.
``(III) The Secretary may by regulation change such total
number.
``(IV) The Secretary may exclude from the applicable number
patients to whom such drugs or combinations of drugs are
directly administered by the qualifying practitioner in the
office setting.
``(iv) If the Secretary by regulation increases the total
number of patients which a qualifying practitioner is permitted
to treat pursuant to clause (iii)(II), the Secretary shall
require such a practitioner to obtain a written agreement from
each patient, including the patient's signature, that the
patient--
``(I) will receive an initial assessment and
treatment plan and periodic assessments and treatment
plans thereafter;
``(II) will be subject to medication adherence and
substance use monitoring;
``(III) understands available treatment options,
including all drugs approved by the Food and Drug
Administration for the treatment of opioid use
disorder, including their potential risks and benefits;
and
``(IV) understands that receiving regular
counseling services is critical to recovery.
``(v) The practitioner will comply with the reporting
requirements of subparagraph (D)(i)(IV).'';
(2) in subparagraph (D)--
(A) in clause (i), by adding at the end the
following:
``(IV) The practitioner reports to the Secretary, at such
times and in such manner as specified by the Secretary, such
information and assurances as the Secretary determines
necessary to assess whether the practitioner continues to meet
the requirements for a waiver under this paragraph.'';
(B) in clause (ii), by striking ``Upon receiving a
notification under subparagraph (B)'' and inserting
``Upon receiving a determination from the Secretary
under clause (iii) finding that a practitioner meets
all requirements for a waiver under subparagraph (B)'';
and
(C) in clause (iii)--
(i) by inserting ``and shall forward such
determination to the Attorney General'' before
the period at the end of the first sentence;
and
(ii) by striking ``physician'' and
inserting ``practitioner'';
(3) in subparagraph (G)--
(A) by amending clause (ii)(IV) to read as follows:
``(IV) The physician has, with respect to the
treatment and management of opiate-dependent patients,
completed not less than 8 hours of training (through
classroom situations, seminars at professional society
meetings, electronic communications, or otherwise) that
is provided by the American Society of Addiction
Medicine, the American Academy of Addiction Psychiatry,
the American Medical Association, the American
Osteopathic Association, the American Psychiatric
Association, or any other organization that the
Secretary determines is appropriate for purposes of
this subclause. Such training shall address--
``(aa) opioid maintenance and
detoxification;
``(bb) appropriate clinical use of all
drugs approved by the Food and Drug
Administration for the treatment of opioid use
disorder;
``(cc) initial and periodic patient
assessments (including substance use
monitoring);
``(dd) individualized treatment planning;
overdose reversal; relapse prevention;
``(ee) counseling and recovery support
services;
``(ff) staffing roles and considerations;
``(gg) diversion control; and
``(hh) other best practices, as identified
by the Secretary.''; and
(B) by adding at the end the following:
``(iii) The term `qualifying practitioner' means--
``(I) a qualifying physician, as defined in clause
(ii); or
``(II) during the period beginning on the date of
the enactment of the Opioid Use Disorder Treatment
Expansion and Modernization Act and ending on the date
that is 3 years after such date of enactment, a
qualifying other practitioner, as defined in clause
(iv).
``(iv) The term `qualifying other practitioner' means a
nurse practitioner or physician assistant who satisfies each of
the following:
``(I) The nurse practitioner or physician assistant
is licensed under State law to prescribe schedule III,
IV, or V medications for the treatment of pain.
``(II) The nurse practitioner or physician
assistant satisfies one or more of the following:
``(aa) Has completed not fewer than 24
hours of initial training addressing each of
the topics listed in clause (ii)(IV) (through
classroom situations, seminars at professional
society meetings, electronic communications, or
otherwise) provided by the American Society of
Addiction Medicine, the American Academy of
Addiction Psychiatry, the American Medical
Association, the American Osteopathic
Association, the American Nurses Credentialing
Center, the American Psychiatric Association,
the American Association of Nurse
Practitioners, the American Academy of
Physician Assistants, or any other organization
that the Secretary determines is appropriate
for purposes of this subclause.
``(bb) Has such other training or
experience as the Secretary determines will
demonstrate the ability of the nurse
practitioner or physician assistant to treat
and manage opiate-dependent patients.
``(III) The nurse practitioner or physician
assistant is supervised by or works in collaboration
with a qualifying physician, if the nurse practitioner
or physician assistant is required by State law to
prescribe medications for the treatment of opioid use
disorder in collaboration with or under the supervision
of a physician.
The Secretary may review and update the requirements for being
a qualifying other practitioner under this clause.''; and
(4) in subparagraph (H)--
(A) in clause (i), by inserting after subclause
(II) the following:
``(III) Such other elements of the requirements under this
paragraph as the Secretary determines necessary for purposes of
implementing such requirements.''; and
(B) by amending clause (ii) to read as follows:
``(ii) Not later than 1 year after the date of enactment of the
Opioid Use Disorder Treatment Expansion and Modernization Act, the
Secretary shall update the treatment improvement protocol containing
best practice guidelines for the treatment of opioid-dependent patients
in office-based settings. The Secretary shall update such protocol in
consultation with experts in opioid use disorder research and
treatment.''.
(b) Recommendation of Revocation or Suspension of Registration in
Case of Substantial Noncompliance.--The Secretary of Health and Human
Services may recommend to the Attorney General that the registration of
a practitioner be revoked or suspended if the Secretary determines,
according to such criteria as the Secretary establishes by regulation,
that a practitioner who is registered under section 303(g)(2) of the
Controlled Substances Act (21 U.S.C. 823(g)(2)) is not in substantial
compliance with the requirements of such section, as amended by this
Act.
(c) Opioid Defined.--Section 102(18) of the Controlled Substances
Act (21 U.S.C. 802(18)) is amended by inserting ``or `opioid''' after
``The term `opiate'''.
(d) Reports to Congress.--
(1) In general.--Not later than 2 years after the date of
enactment of this Act and not less than over every 5 years
thereafter, the Secretary of Health and Human Services, in
consultation with the Drug Enforcement Administration and
experts in opioid use disorder research and treatment, shall--
(A) perform a thorough review of the provision of
opioid use disorder treatment services in the United
States, including services provided in opioid treatment
programs and other specialty and nonspecialty settings;
and
(B) submit a report to the Congress on the findings
and conclusions of such review.
(2) Contents.--Each report under paragraph (1) shall
include an assessment of--
(A) compliance with the requirements of section
303(g)(2) of the Controlled Substances Act (21 U.S.C.
823(g)(2)), as amended by this Act;
(B) the measures taken by the Secretary of Health
and Human Services to ensure such compliance;
(C) whether there is further need to increase or
decrease the number of patients a waivered practitioner
is permitted to treat, as provided for by the amendment
made by subsection (a)(1);
(D) the extent to which, and proportions with
which, the full range of Food and Drug Administration-
approved treatments for opioid use disorder are used in
routine health care settings and specialty substance
use disorder treatment settings;
(E) access to, and use of, counseling and recovery
support services, including the percentage of patients
receiving such services;
(F) changes in State or local policies and
legislation relating to opioid use disorder treatment;
(G) the use of prescription drug monitoring
programs by practitioners who are permitted to dispense
narcotic drugs to individuals pursuant to a waiver
under section 303(g)(2) of the Controlled Substances
Act (21 U.S.C. 823(g)(2));
(H) the findings resulting from inspections by the
Drug Enforcement Administration of practitioners
described in subparagraph (G); and
(I) the effectiveness of cross-agency collaboration
between Department of Health and Human Services and the
Drug Enforcement Administration for expanding effective
opioid use disorder treatment.
SEC. 1704. SENSE OF CONGRESS.
It is the Sense of Congress that, with respect to the total number
of patients that a qualifying physician (as defined in subparagraph
(G)(iii) of section 303(g)(2) of the Controlled Substances Act (21
U.S.C. 823(g)(2)) can treat at any one time pursuant to such section,
the Secretary of Health and Human Services should consider raising such
total number to 250 patients following a third notification to the
Secretary of the need and intent of the physician to treat up to 250
patients that is submitted to the Secretary not sooner than 1 year
after the date on which the physician submitted to the Secretary a
second notification to treat up to 100 patients.
SEC. 1705. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES.
(a) In General.--Section 309 of the Controlled Substances Act (21
U.S.C. 829) is amended by adding at the end the following:
``(f) Partial Fills of Schedule II Controlled Substances.--
``(1) Partial fills.--
``(A) In general.--A prescription for a controlled
substance in schedule II may be partially filled if--
``(i) it is not prohibited by State law;
``(ii) the prescription is written and
filled in accordance with the Controlled
Substances Act (21 U.S.C. 801 et seq.),
regulations prescribed by the Attorney General,
and State law;
``(iii) the partial fill is requested by
the patient or the practitioner that wrote the
prescription; and
``(iv) the total quantity dispensed in all
partial fillings does not exceed the total
quantity prescribed.
``(B) Other circumstances.--A prescription for a
controlled substance in schedule II may be partially
filled in accordance with section 1306.13 of title 21,
Code of Federal Regulations (as in effect on the date
of enactment of the Reducing Unused Medications Act of
2016).
``(2) Remaining portions.--
``(A) In general.--Except as provided in
subparagraph (B), remaining portions of a partially
filled prescription for a controlled substance in
schedule II--
``(i) may be filled; and
``(ii) shall be filled not later than 30
days after the date on which the prescription
is written.
``(B) Emergency situations.--In emergency
situations, as described in subsection (a), the
remaining portions of a partially filled prescription
for a controlled substance in schedule II--
``(i) may be filled; and
``(ii) shall be filled not later than 72
hours after the prescription is issued.''.
(b) Rule of Construction.--Nothing in this section shall be
construed to affect the authority of the Attorney General to allow a
prescription for a controlled substance in schedule III, IV, or V of
section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) to
be partially filled.
TITLE XVIII--NATIONAL ALL SCHEDULES PRESCRIPTION ELECTRONIC REPORTING
REAUTHORIZATION ACT
SEC. 1801. SHORT TITLE.
This title may be cited as the ``National All Schedules
Prescription Electronic Reporting Reauthorization Act of 2015''.
SEC. 1802. AMENDMENT TO PURPOSE.
Paragraph (1) of section 2 of the National All Schedules
Prescription Electronic Reporting Act of 2005 (Public Law 109-60) is
amended to read as follows:
``(1) foster the establishment of State-administered
controlled substance monitoring systems in order to ensure
that--
``(A) health care providers have access to the
accurate, timely prescription history information that
they may use as a tool for the early identification of
patients at risk for addiction in order to initiate
appropriate medical interventions and avert the tragic
personal, family, and community consequences of
untreated addiction; and
``(B) appropriate law enforcement, regulatory, and
State professional licensing authorities have access to
prescription history information for the purposes of
investigating drug diversion and prescribing and
dispensing practices of errant prescribers or
pharmacists; and''.
SEC. 1803. AMENDMENTS TO CONTROLLED SUBSTANCE MONITORING PROGRAM.
Section 399O of the Public Health Service Act (42 U.S.C. 280g-3) is
amended--
(1) in subsection (a)--
(A) in paragraph (1)--
(i) in subparagraph (A), by striking
``or'';
(ii) in subparagraph (B), by striking the
period at the end and inserting ``; or''; and
(iii) by adding at the end the following:
``(C) to maintain and operate an existing State-
controlled substance monitoring program.''; and
(B) in paragraph (3), by inserting ``by the
Secretary'' after ``Grants awarded'';
(2) by amending subsection (b) to read as follows:
``(b) Minimum Requirements.--The Secretary shall maintain and, as
appropriate, supplement or revise (after publishing proposed additions
and revisions in the Federal Register and receiving public comments
thereon) minimum requirements for criteria to be used by States for
purposes of clauses (ii), (v), (vi), and (vii) of subsection
(c)(1)(A).'';
(3) in subsection (c)--
(A) in paragraph (1)(B)--
(i) in the matter preceding clause (i), by
striking ``(a)(1)(B)'' and inserting
``(a)(1)(B) or (a)(1)(C)'';
(ii) in clause (i), by striking ``program
to be improved'' and inserting ``program to be
improved or maintained'';
(iii) by redesignating clauses (iii) and
(iv) as clauses (iv) and (v), respectively;
(iv) by inserting after clause (ii) the
following:
``(iii) a plan to apply the latest advances
in health information technology in order to
incorporate prescription drug monitoring
program data directly into the workflow of
prescribers and dispensers to ensure timely
access to patients' controlled prescription
drug history;'';
(v) in clause (iv), as redesignated, by
inserting before the semicolon at the end ``and
at least one health information technology
system such as an electronic health records
system, a health information exchange, or an e-
prescribing system''; and
(vi) in clause (v), as redesignated, by
striking ``public health'' and inserting
``public health or public safety'';
(B) in paragraph (3)--
(i) by striking ``If a State that submits''
and inserting the following:
``(A) In general.--If a State that submits'';
(ii) by striking the period at the end and
inserting ``and include timelines for full
implementation of such interoperability. The
State shall also describe the manner in which
it will achieve interoperability between its
monitoring program and health information
technology systems, as allowable under State
law, and include timelines for implementation
of such interoperability.''; and
(iii) by adding at the end the following:
``(B) Monitoring of efforts.--The Secretary shall
monitor State efforts to achieve interoperability, as
described in subparagraph (A).''; and
(C) in paragraph (5)--
(i) by striking ``implement or improve''
and inserting ``establish, improve, or
maintain''; and
(ii) by adding at the end the following:
``The Secretary shall redistribute any funds
that are so returned among the remaining
grantees under this section in accordance with
the formula described in subsection
(a)(2)(B).'';
(4) in subsection (d)--
(A) in the matter preceding paragraph (1)--
(i) by striking ``In implementing or
improving'' and all that follows through
``(a)(1)(B)'' and inserting ``In establishing,
improving, or maintaining a controlled
substance monitoring program under this
section, a State shall comply, or with respect
to a State that applies for a grant under
subparagraph (B) or (C) of subsection (a)(1)'';
and
(ii) by striking ``public health'' and
inserting ``public health or public safety'';
and
(B) by adding at the end the following:
``(5) The State shall report to the Secretary on--
``(A) as appropriate, interoperability with the
controlled substance monitoring programs of Federal
departments and agencies;
``(B) as appropriate, interoperability with health
information technology systems such as electronic
health records systems, health information exchanges,
and e-prescribing systems; and
``(C) whether or not the State provides automatic,
real-time or daily information about a patient when a
practitioner (or the designee of a practitioner, where
permitted) requests information about such patient.'';
(5) in subsections (e), (f)(1), and (g), by striking
``implementing or improving'' each place it appears and
inserting ``establishing, improving, or maintaining'';
(6) in subsection (f)--
(A) in paragraph (1)--
(i) in subparagraph (B), by striking
``misuse of a schedule II, III, or IV
substance'' and inserting ``misuse of a
controlled substance included in schedule II,
III, or IV of section 202(c) of the Controlled
Substance Act''; and
(ii) in subparagraph (D), by inserting ``a
State substance abuse agency,'' after ``a State
health department,''; and
(B) by adding at the end the following:
``(3) Evaluation and reporting.--Subject to subsection (g),
a State receiving a grant under subsection (a) shall provide
the Secretary with aggregate data and other information
determined by the Secretary to be necessary to enable the
Secretary--
``(A) to evaluate the success of the State's
program in achieving its purposes; or
``(B) to prepare and submit the report to Congress
required by subsection (l)(2).
``(4) Research by other entities.--A department, program,
or administration receiving nonidentifiable information under
paragraph (1)(D) may make such information available to other
entities for research purposes.'';
(7) by redesignating subsections (h) through (n) as
subsections (j) through (p), respectively;
(8) in subsections (c)(1)(A)(iv) and (d)(4), by striking
``subsection (h)'' each place it appears and inserting
``subsection (j)'';
(9) by inserting after subsection (g) the following:
``(h) Education and Access to the Monitoring System.--A State
receiving a grant under subsection (a) shall take steps to--
``(1) facilitate prescriber and dispenser use of the
State's controlled substance monitoring system;
``(2) educate prescribers and dispensers on the benefits of
the system both to them and society; and
``(3) facilitate linkage to the State substance abuse
agency and substance abuse disorder services.
``(i) Consultation With Attorney General.--In carrying out this
section, the Secretary shall consult with the Attorney General of the
United States and other relevant Federal officials to--
``(1) ensure maximum coordination of controlled substance
monitoring programs and related activities; and
``(2) minimize duplicative efforts and funding.'';
(10) in subsection (l)(2)(A), as redesignated by paragraph
(7)--
(A) in clause (ii), by inserting ``; established or
strengthened initiatives to ensure linkages to
substance use disorder services;'' before ``or affected
patient access''; and
(B) in clause (iii), by inserting ``and between
controlled substance monitoring programs and health
information technology systems'' before ``, including
an assessment'';
(11) by striking subsection (m) (relating to preference),
as redesignated by paragraph (7);
(12) by redesignating subsections (n) through (p), as
redesignated by paragraph (7), as subsections (m) through (o),
respectively;
(13) in subsection (m)(1), as redesignated by paragraph
(12), by striking ``establishment, implementation, or
improvement'' and inserting ``establishment, improvement, or
maintenance'';
(14) in subsection (n), as redesignated by paragraph (12)--
(A) in paragraph (5)--
(i) by striking ``means the ability'' and
inserting the following: ``means--
``(A) the ability'';
(ii) by striking the period at the end and
inserting ``; or''; and
(iii) by adding at the end the following:
``(B) sharing of State controlled substance
monitoring program information with a health
information technology system such as an electronic
health records system, a health information exchange,
or an e-prescribing system.'';
(B) in paragraph (7), by striking ``pharmacy'' and
inserting ``pharmacist''; and
(C) in paragraph (8), by striking ``and the
District of Columbia'' and inserting ``, the District
of Columbia, and any commonwealth or territory of the
United States''; and
(15) by amending subsection (o), as redesignated by
paragraph (12), to read as follows:
``(o) Authorization of Appropriations.--To carry out this section,
there is authorized to be appropriated $10,000,000 for each of fiscal
years from 2016 through 2020.''.
Amend the title so as to read: ``An Act to authorize the
Attorney General and Secretary of Health and Human Services to
award grants to address the national epidemics of prescription
opioid abuse and heroin use, and to provide for the
establishment of an inter-agency task force to review, modify,
and update best practices for pain management and prescribing
pain medication, and for other purposes.''.
Attest:
Clerk.
114th CONGRESS
2d Session
S. 524
_______________________________________________________________________
AMENDMENTS